{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 151655, "items": [{"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T08:42:06Z", "timestamp": 1575103326937}, "reference-count": 71, "publisher": "Springer Science and Business Media LLC", "issue": "50", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2003, 11, 1]], "date-time": "2003-11-01T00:00:00Z", "timestamp": 1067644800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncogene"], "published-print": {"date-parts": [[2003, 11]]}, "DOI": "10.1038/sj.onc.1206972", "type": "journal-article", "created": {"date-parts": [[2003, 11, 6]], "date-time": "2003-11-06T14:06:56Z", "timestamp": 1068127616000}, "page": "8102-8116", "source": "Crossref", "is-referenced-by-count": 52, "title": ["TACC1\u2013chTOG\u2013Aurora A protein complex in breast cancer"], "prefix": "10.1038", "volume": "22", "author": [{"given": "Nathalie", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "B\u00e9n\u00e9dicte", "family": "Delaval", "sequence": "additional", "affiliation": []}, {"given": "Christophe", "family": "Ginestier", "sequence": "additional", "affiliation": []}, {"given": "Alexia", "family": "Ferrand", "sequence": "additional", "affiliation": []}, {"given": "Daniel", "family": "Isnardon", "sequence": "additional", "affiliation": []}, {"given": "Christian", "family": "Larroque", "sequence": "additional", "affiliation": []}, {"given": "Claude", "family": "Prigent", "sequence": "additional", "affiliation": []}, {"given": "Bertrand", "family": "S\u00e9raphin", "sequence": "additional", "affiliation": []}, {"given": "Jocelyne", "family": "Jacquemier", "sequence": "additional", "affiliation": []}, {"given": "Daniel", "family": "Birnbaum", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2003, 11, 6]]}, "reference": [{"key": "BF1206972_CR1", "unstructured": "Aitola M, Sadek CM, Gustafsson JA and Pelto-Huikko M . (2003). J. Histochem. Cytochem., 51, 455\u2013469."}, {"key": "BF1206972_CR2", "unstructured": "Anand S, Penrhyn-Lowe S and Venkitaraman AR . (2003). Cancer Cell, 3, 51\u201362."}, {"key": "BF1206972_CR3", "unstructured": "Barbarese E, Kosturko L, D'Sa C and Carson JH . (2002). J. Neurochem., 81 (Suppl. 1), 93\u201394."}, {"key": "BF1206972_CR4", "unstructured": "Barbee SA, Lublin AL and Evans TC . (2002). Curr. Biol., 12, 1502\u20131506."}, {"key": "BF1206972_CR5", "unstructured": "Berdnik D and Knoblich JA . (2002). Curr. Biol., 12, 640\u2013647."}, {"key": "BF1206972_CR6", "unstructured": "Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schyver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ and Plowman GD . (1998). EMBO J., 17, 3052\u20133065."}, {"key": "BF1206972_CR7", "unstructured": "Bischoff JR and Plowman GD . (1999). Trends Cell Biol., 9, 454\u2013459."}, {"key": "BF1206972_CR8", "unstructured": "Blagden SP and Glover DM . (2003). Nat. Cell Biol., 5, 505\u2013511."}, {"key": "BF1206972_CR9", "unstructured": "Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Ad\u00e9la\u00efde J, Margolis B and Birnbaum D . (2000). Nat. Cell. Biol., 2, 407\u2013414."}, {"key": "BF1206972_CR10", "unstructured": "Bouveret E, Rigaut G, Shevchenko A, Wilm M and S\u00e9raphin B . (2000). EMBO J., 19, 1661\u20131671."}, {"key": "BF1206972_CR11", "unstructured": "Brinkley BR . (2001). Trends Cell Biol., 11, 18\u201321."}, {"key": "BF1206972_CR12", "unstructured": "Charrasse S and Larroque C . (2000). Exp. Cell Res., 254, 249\u2013256."}, {"key": "BF1206972_CR13", "unstructured": "Charrasse S, Mazel M, Taviaux S, Berta P, Chow T and Larroque C . (1995). Eur. J. Biochem., 234, 406\u2013413."}, {"key": "BF1206972_CR14", "unstructured": "Charrasse S, Schoeder M, Gauthier-Rouvi\u00e8re C, Ango F, Cassimeris L, Gard DL and Larroque C . (1998). J. Cell Science, 111, 1371\u20131383."}, {"key": "BF1206972_CR15", "unstructured": "Chen H-M, Schmeichel K, Mian LS, Leli\u00e8vre S, Petersen OW and Bissell MJ . (2000). Mol. Biol. Cell, 11, 1357\u20131367."}, {"key": "BF1206972_CR16", "unstructured": "Chen SS, Chang PC, Cheng YW, Tang FL and Lin YS . (2002). EMBO J., 21, 4491\u20134499."}, {"key": "BF1206972_CR17", "unstructured": "Conte N, Charafe-Jauffret E, Delaval B, Ad\u00e9la\u00efde J, Ginestier C, Geneix J, Isnardon D, Jacquemier J and Birnbaum D . (2002). Oncogene, 21, 5619\u20135630."}, {"key": "BF1206972_CR18", "unstructured": "Cremet JY, Descamps S, V\u00e9rit\u00e9 F, Martin A and Prigent C . (2003). Mol. Cell. Biochem., 243, 123\u2013131."}, {"key": "BF1206972_CR19", "unstructured": "Cullen CF and Ohkura H . (2001). Nat. Cell Biol., 31, 637\u2013642."}, {"key": "BF1206972_CR20", "unstructured": "Dutertre S, Descamps S and Prigent C . (2002). Oncogene, 21, 6175\u20136183."}, {"key": "BF1206972_CR21", "unstructured": "Gergely F . (2002). BioEssays, 24, 915\u2013925."}, {"key": "BF1206972_CR22", "unstructured": "Gergely F, Draviam VM and Raff JW . (2003). Genes Dev., 17, 336\u2013341."}, {"key": "BF1206972_CR23", "unstructured": "Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J and Raff JW . (2000a). Proc. Natl. Acad. Sci. USA, 97, 14357\u201315352."}, {"key": "BF1206972_CR24", "unstructured": "Gergely F, Kidd D, Jeffers K, Wakefield JG and Raff JW . (2000b). EMBO J., 19, 241\u2013252."}, {"key": "BF1206972_CR25", "unstructured": "Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C and Glover DM . (2002). J. Cell Biol., 156, 437\u2013451."}, {"key": "BF1206972_CR26", "unstructured": "Giet R and Prigent C . (1999). J. Cell. Science, 112, 3591\u20133601."}, {"key": "BF1206972_CR27", "unstructured": "Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Ad\u00e9la\u00efde J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, Houlgatte R, Birnbaum D and Jacquemier J . (2002). Am. J. Pathol., 161, 1223\u20131233."}, {"key": "BF1206972_CR28", "unstructured": "Groisman I, Huang Y-S, Mendez R, Cao Q, Theurkauf W and Richter JD . (2000). Cell, 103, 435\u2013447."}, {"key": "BF1206972_CR29", "unstructured": "Groisman I, Jung MY, Sarkissian M, Cao Q and Richter JD . (2002). Cell, 109, 473\u2013483."}, {"key": "BF1206972_CR30", "unstructured": "Hao Z, Stoler MH, Sen B, Shore A, Westbrook A, Flickinger CJ, Herr JC and Coonrod SA . (2002). Mol. Reprod. Develop., 63, 291\u2013299."}, {"key": "BF1206972_CR31", "unstructured": "Hirose T, Kawabuchi M, Tamaru T, Okumura N, Nagai K and Okada M . (2000). Eur. J. Biochem., 267, 2113\u20132121."}, {"key": "BF1206972_CR32", "unstructured": "Hirose T, Tamaru T, Okumura N, Nagai K and Okada M . (1997). Eur. J. Biochem., 249, 481\u2013488."}, {"key": "BF1206972_CR33", "unstructured": "Huang X and Madan A . (1999). Genome Res., 9, 868\u2013977."}, {"key": "BF1206972_CR34", "unstructured": "Huang YS, Jung MY, Sarkissian M and Richter JD . (2002). EMBO J., 21, 2139\u20132148."}, {"key": "BF1206972_CR35", "unstructured": "Kr\u00e4mer A, Neben K and Ho AD . (2002). Leukemia, 16, 767\u2013775."}, {"key": "BF1206972_CR36", "unstructured": "Lappin TR, Mullan RN, Stewart JP, Morgan NA, Thompson A and Maxwell AP . (2002). Leuk. Lymphoma, 43, 1455\u20131459."}, {"key": "BF1206972_CR37", "unstructured": "Lauffart B, Gangisetty O and Still IH . (2003). Genomics, 81, 192\u2013201."}, {"key": "BF1206972_CR38", "unstructured": "Lauffart B, Howell SJ, Tasch JE, Cowell JK and Still IH . (2002). Biochem. J., 363, 195\u2013200."}, {"key": "BF1206972_CR39", "unstructured": "Lee MJ, Gergely F, Jeffers K, Peak-Chew SY and Raff JW . (2001). Nat. Cell. Biol., 3, 643\u2013649."}, {"key": "BF1206972_CR40", "unstructured": "Line A, Slucka Z, Stengrevics A, Li G and Rees RC . (2002a). Cancer Genet. Cytogenet., 139, 78\u201383."}, {"key": "BF1206972_CR41", "unstructured": "Line A, Stengrevics A, Slucka Z, Li G, Jankevics E and Rees RC . (2002b). Br. J. Cancer, 86, 1824\u20131830."}, {"key": "BF1206972_CR42", "unstructured": "Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG and Sgroi DC . (2003). Proc. Natl. Acad. Sci. USA, 100, 5974\u20135979."}, {"key": "BF1206972_CR43", "unstructured": "Mack GJ, Ou Y and Rattner JB . (2000). Microscop. Res. Tech., 49, 409\u2013419."}, {"key": "BF1206972_CR44", "unstructured": "McKeveney PJ, Hodges VM, Mullan RN, Maxwell P, Simpson D, Thompson A, Winter PC, Lappin TR and Maxwell AP . (2001). Br. J. Haematol., 112, 1016\u20131024."}, {"key": "BF1206972_CR45", "unstructured": "Mendez R, Barnard D and Richter JD . (2002). EMBO J., 21, 1833\u20131844."}, {"key": "BF1206972_CR46", "unstructured": "Mendez R and Richter JD . (2001). Nat. Rev. Mol. Cell. Biol., 2, 521\u2013529."}, {"key": "BF1206972_CR47", "unstructured": "Miyoshi Y, Iwao K, Egawa C and Noguchi S . (2001). Int. J. Cancer, 92, 370\u2013373."}, {"key": "BF1206972_CR48", "unstructured": "Nigg EA . (2001). Nat. Rev. Mol. Cell Biol., 2, 21\u201332."}, {"key": "BF1206972_CR49", "unstructured": "Nigg EA . (2002). Nat. Rev. Cancer, 2, 1\u201311."}, {"key": "BF1206972_CR50", "unstructured": "Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC and Yaswen P . (2001). Cancer Res., 61, 1250\u20131254."}, {"key": "BF1206972_CR51", "unstructured": "Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L, Rehg J and Ihle JN . (2002). EMBO J., 21, 653\u2013664."}, {"key": "BF1206972_CR52", "unstructured": "Popovici C, Leveugle M, Birnbaum D and Coulier F . (2001). Biochem. Biophys. Res. Commun., 288, 362\u2013370."}, {"key": "BF1206972_CR53", "unstructured": "Pu JJ, Li C, Rodriguez M and Banerjee D . (2001). Cytokine, 13, 129\u2013137."}, {"key": "BF1206972_CR54", "unstructured": "Raff JW . (2002). Trends Cell Biol., 12, 222\u2013225."}, {"key": "BF1206972_CR55", "unstructured": "Ramaswamy S, Ross KN, Lander ES and Golub TR . (2003). Nat. Genet., 33, 1\u20136."}, {"key": "BF1206972_CR56", "unstructured": "Richter JD . (2001). Proc. Natl. Acad. Sci. USA, 98, 7069\u20137071."}, {"key": "BF1206972_CR57", "unstructured": "Roghi C, Giet R, Uzbekov R, Morin N, Chartrain I, Le Guellec R, Couturier A, Dor\u00e9e M, Philippe M and Prigent C . (1998). J. Cell. Sci., 111, 557\u2013572."}, {"key": "BF1206972_CR58", "unstructured": "Sadek CM, Jalaguier S, Feeney E, Aitola M, Damdimopoulos AE, Pelto-Huikko M and Gustafsson J-A . (2000). Mech. Develop., 97, 13\u201326."}, {"key": "BF1206972_CR59", "unstructured": "Sadek CM, Pelto-Huikko M, Tujague M, Steffensen KR, Wennerholm M and Gustafsson JA . (2003). Gene Exp. Patterns, 3, 203\u2013211."}, {"key": "BF1206972_CR60", "unstructured": "Salgado-Garrido J, Bragado-Nilsson E, Kandels-Lewis S and S\u00e9raphin B . (1999). EMBO J., 18, 3451\u20133462."}, {"key": "BF1206972_CR61", "unstructured": "Schweinfest CW, Graber MW, Chapman JM, Papas TS, Baron PL and Watson DK . (1997). Cancer Res., 57, 2961\u20132965."}, {"key": "BF1206972_CR62", "unstructured": "Selenko P, Sprangers R, Stier G, Buhler D, Fischer U and Sattler M . (2001). Nat. Struct. Biol., 8, 27\u201331."}, {"key": "BF1206972_CR63", "unstructured": "Sen S, Zhou H and White RA . (1997). Oncogene, 14, 2195\u20132200."}, {"key": "BF1206972_CR64", "unstructured": "Spittle C, Charrasse S, Larroque C and Cassimeris L . (2000). J. Biol. Chem., 275, 20748\u201320753."}, {"key": "BF1206972_CR65", "unstructured": "Steadman BT, Schmidt PH, Shanks RA, Lapierre LA and Goldenring JR . (2002). J. Biol. Chem., 363, 195\u2013200."}, {"key": "BF1206972_CR66", "unstructured": "Stebbins-Boaz B, Cao Q, de Moor CH, Mendez R and Richter JD . (1999). Mol. Cell, 4, 1017\u20131027."}, {"key": "BF1206972_CR67", "unstructured": "Still IH, Hamilton M, Vince P, Wolfman A and Cowell JK . (1999a). Oncogene, 18, 4032\u20134038."}, {"key": "BF1206972_CR68", "unstructured": "Still IH, Vince P and Cowell JK . (1999b). Genomics, 58, 165\u2013170."}, {"key": "BF1206972_CR69", "unstructured": "Tharun S, He W, Mayes AE, Lennertz P, Beggs JD and Parker R . (2000). Nature, 404, 515\u2013518."}, {"key": "BF1206972_CR70", "unstructured": "Theurkauf WE . (2001). Nat. Cell Biol., 3, E159\u2013E161."}, {"key": "BF1206972_CR71", "unstructured": "Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR and Sen S . (1998). Nat. Genet., 20, 89\u201393."}], "container-title": ["Oncogene"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1206972.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1206972", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1206972.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T19:57:18Z", "timestamp": 1552766238000}, "score": 48.724426, "issued": {"date-parts": [[2003, 11]]}, "references-count": 71, "journal-issue": {"published-print": {"date-parts": [[2003, 11]]}, "issue": "50"}, "alternative-id": ["BF1206972"], "URL": "http://dx.doi.org/10.1038/sj.onc.1206972", "relation": {"cites": []}, "ISSN": ["0950-9232", "1476-5594"], "issn-type": [{"value": "0950-9232", "type": "print"}, {"value": "1476-5594", "type": "electronic"}], "subject": ["Genetics", "Cancer Research", "Molecular Biology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T22:41:23Z", "timestamp": 1574116883543}, "reference-count": 44, "publisher": "Springer Science and Business Media LLC", "issue": "26", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2004, 4, 5]], "date-time": "2004-04-05T00:00:00Z", "timestamp": 1081123200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncogene"], "published-print": {"date-parts": [[2004, 6]]}, "DOI": "10.1038/sj.onc.1207593", "type": "journal-article", "created": {"date-parts": [[2004, 4, 5]], "date-time": "2004-04-05T10:36:18Z", "timestamp": 1081161378000}, "page": "4516-4522", "source": "Crossref", "is-referenced-by-count": 30, "title": ["Aurora B -TACC1 protein complex in cytokinesis"], "prefix": "10.1038", "volume": "23", "author": [{"given": "B\u00e9n\u00e9dicte", "family": "Delaval", "sequence": "first", "affiliation": []}, {"given": "Alexia", "family": "Ferrand", "sequence": "additional", "affiliation": []}, {"given": "Nathalie", "family": "Conte", "sequence": "additional", "affiliation": []}, {"given": "Christian", "family": "Larroque", "sequence": "additional", "affiliation": []}, {"given": "Dani\u00e8le", "family": "Hernandez-Verdun", "sequence": "additional", "affiliation": []}, {"given": "Claude", "family": "Prigent", "sequence": "additional", "affiliation": []}, {"given": "Daniel", "family": "Birnbaum", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2004, 4, 5]]}, "reference": [{"key": "BF1207593_CR1", "unstructured": "Adams RR, Carmena M and Earnshaw WC . (2001). Trends Cell Biol., 11, 49\u201354.", "DOI": "10.1016/S0962-8924(00)01880-8", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR2", "unstructured": "Bischoff JR and Plowman GD . (1999). Trends Cell Biol., 9, 454\u2013459.", "DOI": "10.1016/S0962-8924(99)01658-X", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR3", "unstructured": "Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J and Stukenberg PT . (2002). Mol. Cell Biol., 13, 3064\u20133077.", "DOI": "10.1091/mbc.e02-02-0092", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR4", "unstructured": "Carmena M and Earnshaw WC . (2003). Nat. Rev. Mol. Cell Biol., 4, 842\u2013854.", "DOI": "10.1038/nrm1245", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR5", "unstructured": "Charrasse S, Lorca T, Dor\u00e9e M and Larroque C . (2000). Exp. Cell Res., 254, 249\u2013256.", "DOI": "10.1006/excr.1999.4740", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR6", "unstructured": "Charrasse S, Mazel M, Taviaux S, Berta P, Chow T and Larroque C . (1995). Eur. J. Biochem., 234, 406\u2013413.", "DOI": "10.1111/j.1432-1033.1995.406_b.x", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR7", "unstructured": "Chen H-M, Schmeichel K, Mian LS, Leli\u00e8vre S, Petersen OW and Bissell MJ . (2000). Mol. Cell. Biol., 11, 1357\u20131367.", "DOI": "10.1091/mbc.11.4.1357", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR8", "unstructured": "Conte N, Charafe-Jauffret E, Delaval B, Ad\u00e9la\u00efde J, Ginestier C, Geneix J, Isnardon D, Jacquemier J and Birnbaum D . (2002). Oncogene, 21, 5619\u20135630.", "DOI": "10.1038/sj.onc.1205658", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR9", "unstructured": "Conte N, Delaval B, Ginestier C, Ferrand A, Isnardon D, Larroque C, Prigent C, S\u00e9raphin B, Jacquemier J and Birnbaum D . (2003). Oncogene, 22, 8102\u20138116.", "DOI": "10.1038/sj.onc.1206972", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR10", "unstructured": "Cr\u00e9met J-Y, Descamps S, V\u00e9rit\u00e9 F, Martin A and Prigent C . (2003). Mol. Cell. Biochem., 243, 123\u2013131.", "DOI": "10.1023/A:1021608012253", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR11", "unstructured": "Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N and Taylor SS . (2003). J. Cell Biol., 161, 267\u2013280.", "DOI": "10.1083/jcb.200208091", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR12", "unstructured": "Gergely F . (2002). BioEssays, 24, 915\u2013925.", "DOI": "10.1002/bies.10162", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR13", "unstructured": "Gergely F, Draviam VM and Raff JW . (2003). Genes Dev., 17, 336\u2013341.", "DOI": "10.1101/gad.245603", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR14", "unstructured": "Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C and Glover DM . (2002). J. Cell Biol., 156, 437\u2013451.", "DOI": "10.1083/jcb.200108135", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR15", "unstructured": "Giet R and Prigent CJ . (1999). Cell Sci., 112, 3591\u20133601."}, {"key": "BF1207593_CR16", "unstructured": "Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL and Peters JM . (2003). J. Cell Biol., 161, 281\u2013294.", "DOI": "10.1083/jcb.200208092", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR17", "unstructured": "Hernandez-Verdun D, Roussel P and Gebrane-Younes J . (2002). J. Cell Sci., 115, 2265\u20132270."}, {"key": "BF1207593_CR18", "unstructured": "Honda R, Korner R and Nigg EA . (2003). Mol. Cell. Biol., 14, 3325\u20133341.", "DOI": "10.1091/mbc.e02-11-0769", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR19", "unstructured": "Kallio MJ, McCleland ML, Stukenberg PT and Gorbsky GJ . (2002). Curr. Biol., 12, 900\u2013905.", "DOI": "10.1016/S0960-9822(02)00887-4", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR20", "unstructured": "Katayama H, Brinkley WR and Sen S . (2003). Cancer Metast. Rev., 22, 451\u2013464.", "DOI": "10.1023/A:1023789416385", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR21", "unstructured": "Kawajiri A, Yasui Y, Goto H, Tatsuka M, Takahashi M, Nagata K and Inagaki M . (2003). Mol. Cell. Biol., 14, 1489\u20131500.", "DOI": "10.1091/mbc.e02-09-0612", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR22", "unstructured": "Keryer G, Witczak O, Delouvee A, Kemmner WA, Rouillard D, Tasken K and Bornens M . (2003). Mol. Cell. Biol., 14, 2436\u20132446.", "DOI": "10.1091/mbc.e02-09-0614", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR23", "unstructured": "Lappin TR, Mullan RN, Stewart JP, Morgan NA, Thompson A and Maxwell AP . (2002). Leukamia Lymphoma, 43, 1455\u20131459.", "DOI": "10.1080/1042819022386644", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR24", "unstructured": "Lauffart B, Howell SJ, Tasch JE, Cowell JK and Still IH . (2002). Biochem. J., 363, 195\u2013200.", "DOI": "10.1042/bj3630195", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR25", "unstructured": "Marasco WA, Szilvay AM, Kalland KH, Helland DG, Reyes HM and Walter RJ . (1994). Arch. Virol., 139, 133\u2013154.", "DOI": "10.1007/BF01309460", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR26", "unstructured": "Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, Hendzel M, Chan G and Pilarski LM . (2003). Mol. Cell Biol., 14, 2262\u20132276.", "DOI": "10.1091/mbc.e02-07-0377", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR27", "unstructured": "Minoshima Y, Kawashima T, Hirose K, Tonozuka Y, Kawajiri A, Bao YC, Deng X, Tatsuka M, Narumiya S, May Jr. WS, Nosaka T, Semba K, Inoue T, Satoh T, Inagaki M and Kitamura T . (2003). Dev. Cell, 4, 549\u2013560.", "DOI": "10.1016/S1534-5807(03)00089-3", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR28", "unstructured": "Murnion ME, Adams RR, Callister DM, Allis CD, Earnshaw WC and Swedlow JR . (2001). J. Biol. Chem., 276, 26656\u201326665.", "DOI": "10.1074/jbc.M102288200", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR29", "unstructured": "Nigg EA . (2001). Nat. Rev. Mol. Cell. Biol., 2, 21\u201332.", "DOI": "10.1038/35048096", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR30", "unstructured": "Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L, Rehg J and Ihle JN . (2002). EMBO J., 21, 653\u2013664.", "DOI": "10.1093/emboj/21.4.653", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR31", "unstructured": "Robinson DN and Spudich JA . (2000). Trends Cell Biol., 10, 228\u2013237.", "DOI": "10.1016/S0962-8924(00)01747-5", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR32", "unstructured": "Roussel P, Andr\u00e9 C, Masson C, G\u00e9raud G and Hernandez-Verdun D . (1993). J. Cell Sci., 104, 327\u2013337."}, {"key": "BF1207593_CR33", "unstructured": "Schumacher JM, Golden A and Donovan PJ . (1998). J. Cell Biol., 143, 1635\u20131646.", "DOI": "10.1083/jcb.143.6.1635", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR34", "unstructured": "Steadman BT, Schmidt PH, Shanks RA, Lapierre LA and Goldenring JR . (2002). J. Biol. Chem., 277, 30165\u201330176.", "DOI": "10.1074/jbc.M201914200", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR35", "unstructured": "Stebbins-Boaz B, Cao Q, de Moor CH, Mendez R and Richter JD . (1999). Mol. Cell, 4, 1017\u20131027.", "DOI": "10.1016/S1097-2765(00)80230-0", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR36", "unstructured": "Still IH, Hamilton M, Vince P, Wolfman A and Cowell JK . (1999a). Oncogene, 18, 4032\u20134038.", "DOI": "10.1038/sj.onc.1202801", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR37", "unstructured": "Still IH, Vince P and Cowell JK . (1999b). Genomics, 58, 165\u2013170.", "DOI": "10.1006/geno.1999.5829", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR38", "unstructured": "Sugiyama K, Sugiura K, Hara T, Sugimoto K, Shima H, Honda K, Furukawa K, Yamashita S and Urano T . (2002). Oncogene, 21, 3103\u20133111.", "DOI": "10.1038/sj.onc.1205432", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR39", "unstructured": "Takahashi M, Shibata H, Shimakawa M, Miyamoto M, Mukai H and Ono Y . (1999). J. Biol. Chem., 274, 17267\u201317274.", "DOI": "10.1074/jbc.274.24.17267", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR40", "unstructured": "Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F and Terada Y . (1998). Cancer Res., 58, 4811\u20134816."}, {"key": "BF1207593_CR41", "unstructured": "Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S and Otsu M . (1998). EMBO J., 17, 667\u2013766.", "DOI": "10.1093/emboj/17.3.667", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR42", "unstructured": "Terada Y . (2001). Cell Struct. Funct., 26, 653\u2013657.", "DOI": "10.1247/csf.26.653", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR43", "unstructured": "Tien AC, Lin MH, Su LJ, Hong YR, Cheng TS, Lee YC, Lin WJ, Still IH and Huang CY . (2004). Mol. Cell Proteomics, 3, 93\u2013104.", "DOI": "10.1074/mcp.M300072-MCP200", "doi-asserted-by": "crossref"}, {"key": "BF1207593_CR44", "unstructured": "Wheatley SP, Carvalho A, Vagnarelli P and Earnshaw WC . (2001). Curr Biol., 11, 886\u2013890.", "DOI": "10.1016/S0960-9822(01)00238-X", "doi-asserted-by": "crossref"}], "container-title": ["Oncogene"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1207593.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1207593", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1207593.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 18]], "date-time": "2019-03-18T13:24:55Z", "timestamp": 1552915495000}, "score": 37.503937, "issued": {"date-parts": [[2004, 4, 5]]}, "references-count": 44, "journal-issue": {"published-print": {"date-parts": [[2004, 6]]}, "issue": "26"}, "alternative-id": ["BF1207593"], "URL": "http://dx.doi.org/10.1038/sj.onc.1207593", "relation": {"cites": []}, "ISSN": ["0950-9232", "1476-5594"], "issn-type": [{"value": "0950-9232", "type": "print"}, {"value": "1476-5594", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T03:49:46Z", "timestamp": 1574308186108}, "reference-count": 4, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 6, 1]], "date-time": "2009-06-01T00:00:00Z", "timestamp": 1243814400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2009, 6]]}, "DOI": "10.1186/bcr2281", "type": "journal-article", "created": {"date-parts": [[2009, 6, 23]], "date-time": "2009-06-23T18:14:47Z", "timestamp": 1245780887000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Future role of bevacizumab in breast cancer"], "prefix": "10.1186", "volume": "11", "author": [{"given": "PF", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "S", "family": "Giovannelli", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 6, 23]]}, "reference": [{"key": "2245_CR1", "doi-asserted-by": "publisher", "first-page": "792", "DOI": "10.1200/JCO.2005.05.098", "volume": "23", "author": "KD Miller", "year": "2005", "unstructured": "Miller KD, Holmes FA, et al: Randomised phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005, 23: 792-799. 10.1200/JCO.2005.05.098.", "journal-title": "J Clin Oncol"}, {"key": "2245_CR2", "doi-asserted-by": "publisher", "first-page": "2666", "DOI": "10.1056/NEJMoa072113", "volume": "357", "author": "KD Miller", "year": "2007", "unstructured": "Miller KD, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113.", "journal-title": "N Engl J Med"}, {"key": "2245_CR3", "doi-asserted-by": "crossref", "first-page": "Abstract 1011", "DOI": "10.1200/jco.2008.26.15_suppl.lba1011", "volume": "26", "author": "D Miles", "year": "2008", "unstructured": "Miles D, Romieu G, et al: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol. 2008, 26: Abstract 1011-", "journal-title": "J Clin Oncol"}, {"key": "2245_CR4", "doi-asserted-by": "publisher", "first-page": "1559", "DOI": "10.1586/14737140.8.10.1559", "volume": "8", "author": "B Sirohi", "year": "2008", "unstructured": "Sirohi B, Smith K, et al: Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther. 2008, 8: 1559-1568. 10.1586/14737140.8.10.1559.", "journal-title": "Expert Rev Anticancer Ther"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr2281.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr2281/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr2281.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 21]], "date-time": "2019-05-21T01:53:42Z", "timestamp": 1558403622000}, "score": 26.672897, "issued": {"date-parts": [[2009, 6]]}, "references-count": 4, "journal-issue": {"published-print": {"date-parts": [[2009, 6]]}, "issue": "S1"}, "alternative-id": ["2245"], "URL": "http://dx.doi.org/10.1186/bcr2281", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "article-number": "S20"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T13:15:27Z", "timestamp": 1574428527390}, "reference-count": 68, "publisher": "Korean Breast Cancer Society (KAMJE)", "issue": "1", "license": [{"URL": "http://creativecommons.org/licenses/by-nc/3.0/", "start": {"date-parts": [[2006, 1, 1]], "date-time": "2006-01-01T00:00:00Z", "timestamp": 1136073600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["synapse.koreamed.org"], "crossmark-restriction": false}, "short-container-title": ["J Breast Cancer"], "published-print": {"date-parts": [[2006]]}, "DOI": "10.4048/jbc.2006.9.1.4", "type": "journal-article", "created": {"date-parts": [[2010, 5, 8]], "date-time": "2010-05-08T07:30:21Z", "timestamp": 1273303821000}, "page": "4", "update-policy": "http://dx.doi.org/10.4048/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Current State of the Treatment in Metastatic Breast Cancer"], "prefix": "10.4048", "volume": "9", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": [{"name": "Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 41100 Modena, Italy."}]}, {"given": "Carmelo", "family": "Bengala", "sequence": "additional", "affiliation": [{"name": "Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia Via del Pozzo, 71 41100 Modena, Italy."}]}], "member": "2483", "container-title": ["Journal of Breast Cancer"], "language": "en", "link": [{"URL": "https://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2006.9.1.4", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://synapse.koreamed.org/pdf/10.4048/jbc.2006.9.1.4", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2006.9.1.4", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 8]], "date-time": "2019-06-08T02:43:54Z", "timestamp": 1559961834000}, "score": 26.672897, "issued": {"date-parts": [[2006]]}, "references-count": 68, "journal-issue": {"published-print": {"date-parts": [[2006]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.4048/jbc.2006.9.1.4", "ISSN": ["1738-6756"], "issn-type": [{"value": "1738-6756", "type": "print"}], "assertion": [{"value": "https://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2006.9.1.4", "URL": "https://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2006.9.1.4", "name": "synapse", "label": "Synapse", "group": {"name": "multiple_resolution", "label": "Full text available at:"}}, {"value": "http://ejbc.kr/DOIx.php?id=10.4048/jbc.2006.9.1.4", "URL": "http://ejbc.kr/DOIx.php?id=10.4048/jbc.2006.9.1.4", "name": "the_journal", "label": "the Journal", "group": {"name": "multiple_resolution", "label": "Full text available at:"}}, {"value": "2006-03-31", "name": "published_online", "label": "Published online", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "Copyright \u00a9 2006 Korean Breast Cancer Society", "name": "copyright", "label": "Copyright", "group": {"name": "Copyright_and_licensing", "label": "Copyright and Licensing"}}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T22:14:22Z", "timestamp": 1575152062723}, "reference-count": 7, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 5, 1]], "date-time": "2005-05-01T00:00:00Z", "timestamp": 1114905600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2005, 5]]}, "DOI": "10.1186/bcr1229", "type": "journal-article", "created": {"date-parts": [[2005, 5, 28]], "date-time": "2005-05-28T06:13:36Z", "timestamp": 1117260816000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Oral vinorelbine in metastatic breast cancer"], "prefix": "10.1186", "volume": "7", "author": [{"given": "PF", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "S", "family": "Giovannelli", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 5, 27]]}, "reference": [{"key": "1227_CR1", "unstructured": "Bonneterre J, Senac I, Variol P, Daniel P: Dose finding study of weekly oral vinorelbine in patients with advanced breast cancer. Institute de Recherche Pierre Fabre, Castres, France. Iternational study report PM 259 IN M 156."}, {"key": "1227_CR2", "doi-asserted-by": "publisher", "first-page": "1677", "DOI": "10.1023/A:1013567022670", "volume": "12", "author": "A Depierre", "year": "2001", "unstructured": "Depierre A, Freyer G, Jassem J, et al: Oral vinorelbine: feasibility and safety profile. Ann Oncol. 2001, 12: 1677-1681. 10.1023/A:1013567022670.", "journal-title": "Ann Oncol"}, {"key": "1227_CR3", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1007/s00228-002-0506-x", "volume": "58", "author": "P Variol", "year": "2002", "unstructured": "Variol P, Nguyen L, Tranchand B, et al: A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol. 2002, 58: 467-476. 10.1007/s00228-002-0506-x.", "journal-title": "Eur J Clin Pharmacol"}, {"key": "1227_CR4", "doi-asserted-by": "publisher", "first-page": "1643", "DOI": "10.1023/A:1013180903805", "volume": "12", "author": "M Marty", "year": "2001", "unstructured": "Marty M, Fumoleau P, Adenis A, et al: Oral vinorelbine pharmacokinetics and absolute biovailibility study in patients with solid tumors. Ann Oncol. 2001, 12: 1643-1649. 10.1023/A:1013180903805.", "journal-title": "Ann Oncol"}, {"key": "1227_CR5", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1200/jco.2003.09.057", "volume": "21", "author": "G Freyer", "year": "2003", "unstructured": "Freyer G, Delozier T, Lichinister M, et al: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003, 21: 35-40.", "journal-title": "J Clin Oncol"}, {"key": "1227_CR6", "doi-asserted-by": "publisher", "first-page": "547", "DOI": "10.3346/jkms.2004.19.4.547", "volume": "19", "author": "JH Anh", "year": "2004", "unstructured": "Anh JH, Kim SB, Lee JS, et al: Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci. 2004, 19: 547-553.", "journal-title": "J Korean Med Sci"}, {"key": "1227_CR7", "unstructured": "Ghosn M, Kattan J, Farhat F, et al: Navelbine capecitabine combination: the new first line chemotherapy regimen for metastatic breast cancer. Breast Cancer Res Treat. 2002, 531-Suppl 1"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr1229.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr1229/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr1229.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 16]], "date-time": "2017-06-16T10:17:31Z", "timestamp": 1497608251000}, "score": 26.672897, "issued": {"date-parts": [[2005, 5]]}, "references-count": 7, "journal-issue": {"published-print": {"date-parts": [[2005, 5]]}, "issue": "S1"}, "alternative-id": ["1227"], "URL": "http://dx.doi.org/10.1186/bcr1229", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"], "article-number": "S25"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:47:12Z", "timestamp": 1574538432709}, "reference-count": 9, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2002, 8, 1]], "date-time": "2002-08-01T00:00:00Z", "timestamp": 1028160000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2002, 8]]}, "DOI": "10.1016/s1526-8209(11)70183-5", "type": "journal-article", "created": {"date-parts": [[2011, 8, 31]], "date-time": "2011-08-31T21:02:21Z", "timestamp": 1314824541000}, "page": "217", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Bisphosphonates and Cancer: A Commentary"], "prefix": "10.1016", "volume": "3", "author": [{"given": "Pier Franco", "family": "Conte", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526820911701835?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526820911701835?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 30]], "date-time": "2018-11-30T10:51:28Z", "timestamp": 1543575088000}, "score": 25.596245, "issued": {"date-parts": [[2002, 8]]}, "references-count": 9, "journal-issue": {"published-print": {"date-parts": [[2002, 8]]}, "issue": "3"}, "alternative-id": ["S1526820911701835"], "URL": "http://dx.doi.org/10.1016/s1526-8209(11)70183-5", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T02:35:12Z", "timestamp": 1574476512171}, "reference-count": 110, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 6, 1]], "date-time": "2012-06-01T00:00:00Z", "timestamp": 1338508800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1016/j.clbc.2012.03.005", "type": "journal-article", "created": {"date-parts": [[2012, 5, 16]], "date-time": "2012-05-16T05:52:26Z", "timestamp": 1337147546000}, "page": "157-166", "source": "Crossref", "is-referenced-by-count": 7, "title": ["The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer"], "prefix": "10.1016", "volume": "12", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "Valentina", "family": "Guarneri", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S152682091200081X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S152682091200081X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 23]], "date-time": "2018-11-23T12:23:15Z", "timestamp": 1542975795000}, "score": 25.424877, "issued": {"date-parts": [[2012, 6]]}, "references-count": 110, "journal-issue": {"published-print": {"date-parts": [[2012, 6]]}, "issue": "3"}, "alternative-id": ["S152682091200081X"], "URL": "http://dx.doi.org/10.1016/j.clbc.2012.03.005", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T22:14:22Z", "timestamp": 1575152062769}, "reference-count": 12, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 5, 1]], "date-time": "2005-05-01T00:00:00Z", "timestamp": 1114905600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2005, 5]]}, "DOI": "10.1186/bcr1231", "type": "journal-article", "created": {"date-parts": [[2005, 5, 28]], "date-time": "2005-05-28T06:13:36Z", "timestamp": 1117260816000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Targeting the right chemotherapy for the right patient"], "prefix": "10.1186", "volume": "7", "author": [{"given": "PF", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "V", "family": "Guarneri", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 5, 27]]}, "reference": [{"key": "1229_CR1", "doi-asserted-by": "publisher", "first-page": "3439", "DOI": "10.1200/JCO.1998.16.10.3439", "volume": "16", "author": "R Fossati", "year": "1998", "unstructured": "Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol . 1998, 16: 3439-3460.", "journal-title": "J Clin Oncol"}, {"key": "1229_CR2", "unstructured": "Ghersi D, Wilcken N, Simes J, et al: Taxane containing regimens for metastatic breast cancer. The Cochrane Library. 2003, 3", "DOI": "10.1002/14651858.CD003366", "doi-asserted-by": "crossref"}, {"key": "1229_CR3", "first-page": "22", "volume": "22", "author": "SKL Chia", "year": "2003", "unstructured": "Chia SKL, Speers C, Kang A, et al: The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 22-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "1229_CR4", "doi-asserted-by": "publisher", "first-page": "3302", "DOI": "10.1200/JCO.2004.08.095", "volume": "22", "author": "F Andre", "year": "2004", "unstructured": "Andre F, Slimane K, Bachelot T, et al: Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004, 22: 3302-3308. 10.1200/JCO.2004.08.095.", "journal-title": "J Clin Oncol"}, {"key": "1229_CR5", "doi-asserted-by": "publisher", "first-page": "44", "DOI": "10.1002/cncr.11859", "volume": "100", "author": "SH Giordano", "year": "2004", "unstructured": "Giordano SH, Buzdar AU, Smith TL, et al: Is breast cancer survival improving?. Cancer. 2004, 100: 44-52. 10.1002/cncr.11859.", "journal-title": "Cancer"}, {"key": "1229_CR6", "doi-asserted-by": "publisher", "first-page": "2197", "DOI": "10.1200/JCO.1996.14.8.2197", "volume": "14", "author": "PA Greenberg", "year": "1996", "unstructured": "Greenberg PA, Hortobagyi GN, Smith TL, et al: Long term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996, 14: 2197-2205.", "journal-title": "J Clin Oncol"}, {"key": "1229_CR7", "doi-asserted-by": "publisher", "first-page": "885", "DOI": "10.1001/jama.285.7.885", "volume": "285", "author": "R Yancik", "year": "2001", "unstructured": "Yancik R, Wesley M, Ries L, et al: Effect of age and comorbidity in postmenopausal breast cancer patients. JAMA. 2001, 285: 885-892. 10.1001/jama.285.7.885.", "journal-title": "JAMA"}, {"key": "1229_CR8", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1023/A:1011945623464", "volume": "68", "author": "PF Conte", "year": "2001", "unstructured": "Conte PF, Gennari A, Donati S, et al: Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001, 68: 171-179. 10.1023/A:1011945623464.", "journal-title": "Breast Cancer Res Treat"}, {"key": "1229_CR9", "doi-asserted-by": "publisher", "first-page": "31", "DOI": "10.1038/sj.bjc.6601518", "volume": "90", "author": "F Cappuzzo", "year": "2004", "unstructured": "Cappuzzo F, Mazzoni F, Gennari A, et al: Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer. 2004, 90: 31-35. 10.1038/sj.bjc.6601518.", "journal-title": "Br J Cancer"}, {"key": "1229_CR10", "doi-asserted-by": "publisher", "first-page": "704", "DOI": "10.1002/cncr.20400", "volume": "101", "author": "PF Conte", "year": "2004", "unstructured": "Conte PF, Guarneri V, Bruzzi P, et al: Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer. 2004, 101: 704-712. 10.1002/cncr.20400.", "journal-title": "Cancer"}, {"key": "1229_CR11", "doi-asserted-by": "publisher", "first-page": "783", "DOI": "10.1056/NEJM200103153441101", "volume": "344", "author": "DJ Slamon", "year": "2001", "unstructured": "Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.", "journal-title": "N Engl J Med"}, {"key": "1229_CR12", "doi-asserted-by": "publisher", "first-page": "962", "DOI": "10.1038/sj.bjc.6601634", "volume": "90", "author": "A Gennari", "year": "2004", "unstructured": "Gennari A, Bruzzi P, Orlandini C, et al: Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent from type of adjuvant therapy. Br J Cancer. 2004, 90: 962-967. 10.1038/sj.bjc.6601634.", "journal-title": "Br J Cancer"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr1231.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr1231/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr1231.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 16]], "date-time": "2017-06-16T10:17:19Z", "timestamp": 1497608239000}, "score": 24.805717, "issued": {"date-parts": [[2005, 5]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[2005, 5]]}, "issue": "S1"}, "alternative-id": ["1229"], "URL": "http://dx.doi.org/10.1186/bcr1231", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"], "article-number": "S27"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:25Z", "timestamp": 1575305965663}, "reference-count": 104, "publisher": "Elsevier BV", "issue": "11", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 12, 1]], "date-time": "2007-12-01T00:00:00Z", "timestamp": 1196467200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2007, 12]]}, "DOI": "10.3816/cbc.2007.n.048", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:07:45Z", "timestamp": 1221095265000}, "page": "841-849", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Evolving Nonendocrine Therapeutic Options for Metastatic Breast Cancer: How Adjuvant Chemotherapy Influences Treatment"], "prefix": "10.3816", "volume": "7", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "Valentina", "family": "Guarneri", "sequence": "additional", "affiliation": []}, {"given": "Carmelo", "family": "Bengala", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526820911707856?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526820911707856?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T23:00:02Z", "timestamp": 1557788402000}, "score": 23.595306, "issued": {"date-parts": [[2007, 12]]}, "references-count": 104, "journal-issue": {"published-print": {"date-parts": [[2007, 12]]}, "issue": "11"}, "alternative-id": ["S1526820911707856"], "URL": "http://dx.doi.org/10.3816/cbc.2007.n.048", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:54:09Z", "timestamp": 1574283249440}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 3, 1]], "date-time": "2009-03-01T00:00:00Z", "timestamp": 1235865600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2009, 3]]}, "DOI": "10.1016/s1359-6349(09)70002-3", "type": "journal-article", "created": {"date-parts": [[2009, 3, 3]], "date-time": "2009-03-03T09:19:18Z", "timestamp": 1236071958000}, "page": "1-2", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The role of new cytotoxic agents for the treatment of metastatic breast cancer"], "prefix": "10.1016", "volume": "7", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634909700023?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634909700023?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 21]], "date-time": "2018-12-21T08:52:47Z", "timestamp": 1545382367000}, "score": 23.238201, "issued": {"date-parts": [[2009, 3]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 3]]}, "issue": "1"}, "alternative-id": ["S1359634909700023"], "URL": "http://dx.doi.org/10.1016/s1359-6349(09)70002-3", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T15:47:55Z", "timestamp": 1574264875310}, "reference-count": 49, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3165, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Journal"], "published-print": {"date-parts": [[2007, 1]]}, "DOI": "10.1111/j.1524-4741.2006.00359.x", "type": "journal-article", "created": {"date-parts": [[2007, 1, 4]], "date-time": "2007-01-04T21:41:47Z", "timestamp": 1167946907000}, "page": "28-35", "source": "Crossref", "is-referenced-by-count": 32, "title": ["Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective"], "prefix": "10.1111", "volume": "13", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "Antonio", "family": "Frassoldati", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "b1_197", "DOI": "10.1016/S0140-6736(97)11423-4", "doi-asserted-by": "publisher"}, {"key": "b2_198", "DOI": "10.1016/S0140-6736(05)66544-0", "doi-asserted-by": "publisher"}, {"key": "b3_199", "author": "Fisher B", "volume": "4", "first-page": "459", "year": "1986", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1986.4.4.459", "doi-asserted-by": "crossref"}, {"key": "b4_200", "DOI": "10.1093/jnci/88.21.1529", "doi-asserted-by": "publisher"}, {"key": "b5_201", "author": "Swain SM", "volume": "88", "first-page": "1510", "year": "1996", "journal-title": "J Natl Cancer Inst", "DOI": "10.1093/jnci/88.21.1516", "doi-asserted-by": "crossref"}, {"key": "b6_202", "DOI": "10.1016/S0140-6736(02)09088-8", "doi-asserted-by": "publisher"}, {"key": "b7_203", "DOI": "10.1002/cncr.11745", "doi-asserted-by": "publisher"}, {"key": "b8_204", "DOI": "10.1016/S0140-6736(04)17666-6", "doi-asserted-by": "publisher"}, {"key": "b9_205", "DOI": "10.1200/JCO.2005.04.120", "doi-asserted-by": "publisher"}, {"key": "b10_206", "DOI": "10.1056/NEJMoa040331", "doi-asserted-by": "publisher"}, {"key": "b11_207", "DOI": "10.1016/S0140-6736(05)67059-6", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "b12_208", "first-page": "S10", "volume": "94", "author": "Jakesz R", "year": "2005", "journal-title": "Breast Cancer Res Treat"}, {"key": "b13_209", "DOI": "10.1056/NEJMoa052258", "doi-asserted-by": "publisher"}, {"key": "b14_210", "DOI": "10.1056/NEJMoa032312", "doi-asserted-by": "publisher"}, {"key": "b15_211", "author": "Goss PE", "volume": "97", "first-page": "1262", "year": "2005", "journal-title": "J Natl Cancer Inst", "DOI": "10.1093/jnci/dji250", "doi-asserted-by": "crossref"}, {"issue": "1", "key": "b16_212", "first-page": "S10", "volume": "94", "author": "Goss PE", "year": "2005", "journal-title": "Breast Cancer Res Treat"}, {"key": "b17_213", "author": "Howell A", "volume-title": "The ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer - Updated Efficacy Results Based on a Median Follow-up of 5 years"}, {"key": "b18_214", "author": "Thurlimann B", "volume-title": "Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor-Positive Breast Cancer: First Results of IBCSG 18-98/BIG 1-98"}, {"issue": "1", "key": "b19_215", "first-page": "S10", "volume": "94", "author": "Ingle JN", "year": "2005", "journal-title": "Breast Cancer Res Treat"}, {"key": "b20_216", "author": "Jonat W", "volume-title": "Switching from Adjuvant Tamoxifen to Anastrozole in Postmenopausal Women with Hormone-Responsive Early Breast Cancer: A Meta-Analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial"}, {"key": "b21_217", "author": "Robinson E", "volume": "8", "first-page": "329", "year": "1996", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-199608050-00002", "doi-asserted-by": "crossref"}, {"issue": "1", "key": "b22_218", "first-page": "S7", "volume": "88", "author": "Coombes RC", "year": "2004", "journal-title": "Breast Cancer Res Treat"}, {"key": "b23_219", "DOI": "10.1038/sj.bjc.6690188", "doi-asserted-by": "publisher"}, {"key": "b24_220", "author": "Pfeilschifter J", "volume": "18", "first-page": "1570", "year": "2000", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2000.18.7.1570", "doi-asserted-by": "crossref"}, {"key": "b25_221", "DOI": "10.1053/j.seminoncol.2003.08.028", "doi-asserted-by": "publisher"}, {"key": "b26_222", "author": "Powles TJ", "volume": "14", "first-page": "78", "year": "1996", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.1996.14.1.78", "doi-asserted-by": "crossref"}, {"key": "b27_223", "DOI": "10.1016/j.bone.2003.11.006", "doi-asserted-by": "publisher"}, {"key": "b28_224", "DOI": "10.1158/1078-0432.CCR-04-0438", "doi-asserted-by": "publisher"}, {"issue": "14", "key": "b29_225", "first-page": "7s", "volume": "22", "author": "Lonning PE", "year": "2004", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "b30_226", "first-page": "S35", "volume": "88", "author": "Coleman RE", "year": "2004", "journal-title": "Breast Cancer Res Treat"}, {"key": "b31_227", "DOI": "10.1007/s00586-003-0608-x", "doi-asserted-by": "publisher"}, {"key": "b32_228", "author": "Miller E", "volume": "48", "first-page": "122", "year": "2003", "journal-title": "Int J Fertil Womens Med"}, {"key": "b33_229", "DOI": "10.1200/JCO.2003.08.017", "doi-asserted-by": "publisher"}, {"issue": "16", "key": "b34_230", "first-page": "12s", "volume": "23", "author": "Brufsky A", "year": "2005", "journal-title": "J Clin Oncol"}, {"key": "b35_231", "author": "McDonald CC", "volume": "311", "first-page": "977", "year": "1995", "journal-title": "Br Med J", "DOI": "10.1136/bmj.311.7011.977", "doi-asserted-by": "crossref"}, {"key": "b36_232", "DOI": "10.1046/j.1525-1497.2003.20724.x", "doi-asserted-by": "publisher"}, {"key": "b37_233", "DOI": "10.1016/S0140-6736(98)05066-1", "doi-asserted-by": "publisher"}, {"key": "b38_234", "unstructured": "38.Framingham Heart Study . Available at: http://www.nhlbi.nih.gov/about/framingham/index.html (accessed on 6 March 2006)."}, {"key": "b39_235", "DOI": "10.1196/annals.1290.038", "doi-asserted-by": "publisher"}, {"key": "b40_236", "DOI": "10.1016/S1049-3867(01)00075-5", "doi-asserted-by": "publisher"}, {"key": "b41_237", "author": "Harper-Wynne C", "volume": "11", "first-page": "614", "year": "2002", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"key": "b42_238", "DOI": "10.1359/jbmr.2002.17.1.172", "doi-asserted-by": "publisher"}, {"key": "b43_239", "DOI": "10.1093/annonc/mdi158", "doi-asserted-by": "publisher"}, {"key": "b44_240", "unstructured": "44.Arimidex Prescribing Information . Available at: http://www.astrazeneca-us.com/pi/arimidex.pdf (accessed on 6 March 2006."}, {"issue": "14", "key": "b45_241", "first-page": "39s", "volume": "22", "author": "Krag LE", "year": "2004", "journal-title": "J Clin Oncol"}, {"key": "b46_242", "DOI": "10.1007/s10549-005-3783-0", "doi-asserted-by": "publisher"}, {"key": "b47_243", "author": "Goldhirsch A", "volume": "161", "first-page": "569", "year": "2005", "journal-title": "Ann Oncol"}, {"key": "b48_244", "author": "Rieber AG", "volume": "3", "first-page": "309", "year": "2005", "journal-title": "J Natl Compr Canc Netw", "DOI": "10.6004/jnccn.2005.0018", "doi-asserted-by": "crossref"}, {"key": "b49_245", "DOI": "10.1200/JCO.2002.06.020", "doi-asserted-by": "publisher"}], "container-title": ["The Breast Journal"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1524-4741.2006.00359.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 16]], "date-time": "2019-01-16T08:08:59Z", "timestamp": 1547626139000}, "score": 22.994785, "issued": {"date-parts": [[2007, 1]]}, "references-count": 49, "journal-issue": {"published-print": {"date-parts": [[2007, 1]]}, "issue": "1"}, "alternative-id": ["10.1111/j.1524-4741.2006.00359.x"], "URL": "http://dx.doi.org/10.1111/j.1524-4741.2006.00359.x", "relation": {"cites": []}, "ISSN": ["1075-122X", "1524-4741"], "issn-type": [{"value": "1075-122X", "type": "print"}, {"value": "1524-4741", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T12:43:08Z", "timestamp": 1574340188735}, "publisher-location": "Berlin, Heidelberg", "reference-count": 142, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540367802", "type": "print"}, {"value": "9783540367819", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-3-540-36781-9_19", "type": "book-chapter", "created": {"date-parts": [[2007, 12, 21]], "date-time": "2007-12-21T19:53:11Z", "timestamp": 1198266791000}, "page": "239-256", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Progress in the Treatment of Early and Advanced Breast Cancer"], "prefix": "10.1007", "author": [{"given": "Valentina", "family": "Guarneri", "sequence": "first", "affiliation": []}, {"given": "Federico", "family": "Piacentini", "sequence": "additional", "affiliation": []}, {"given": "Pier Franco", "family": "Conte", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "19_CR1", "doi-asserted-by": "crossref", "first-page": "510", "DOI": "10.1200/jco.2004.22.14_suppl.510", "volume": "22", "author": "K.S. Albain", "year": "2004", "unstructured": "Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O\u2019Shaughnessy J, Reyes JM (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival (abstract). Proc Am Soc Clin Oncol 22:510", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "19_CR2", "doi-asserted-by": "publisher", "first-page": "2284", "DOI": "10.1200/JCO.2004.05.166", "volume": "22", "author": "M. Ayers", "year": "2004", "unstructured": "Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol 22:2284\u20132293", "journal-title": "J. Clin. Oncol"}, {"key": "19_CR3", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1093/annonc/mdg069", "volume": "14", "author": "E. Baldini", "year": "2003", "unstructured": "Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF (2003) Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14:227\u2013232", "journal-title": "Ann Oncol"}, {"key": "19_CR4", "doi-asserted-by": "crossref", "first-page": "207", "DOI": "10.1200/JCO.1997.15.1.207", "volume": "15", "author": "H. Bartelink", "year": "1997", "unstructured": "Bartelink H, Rubens RD, van der Schueren E, Sylvester R (1997) Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 15:207\u2013215", "journal-title": "J Clin Oncol"}, {"key": "19_CR5", "doi-asserted-by": "publisher", "first-page": "2131", "DOI": "10.1016/S0140-6736(02)09088-8", "volume": "359", "author": "M. Baum", "year": "2002", "unstructured": "Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131\u20132139", "journal-title": "Lancet"}, {"key": "19_CR6", "doi-asserted-by": "publisher", "first-page": "2019", "DOI": "10.1200/JCO.2005.04.1665", "volume": "24", "author": "H.D. Bear", "year": "2006", "unstructured": "Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019\u20132027", "journal-title": "J Clin Oncol"}, {"key": "19_CR7", "first-page": "104", "volume": "2", "author": "G.T. Beatson", "year": "1898", "unstructured": "Beatson GT (1898) On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1898; 2:104\u2013162", "journal-title": "Lancet"}, {"key": "19_CR8", "unstructured": "Bianco AR, De Matteis A, Manzione L, Boni C, Palazzo S, Di Palma M, Iacono C, De Placido S, Papaldo P, Cognetti F (2006) Sequential Epirubicin-Docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Proc Am Soc Clin Oncol 24 (abstract LBA520)"}, {"key": "19_CR9", "doi-asserted-by": "publisher", "first-page": "3114", "DOI": "10.1200/JCO.2002.11.005", "volume": "20", "author": "L. Biganzoli", "year": "2002", "unstructured": "Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20:3114\u20133121", "journal-title": "J Clin Oncol"}, {"key": "19_CR10", "doi-asserted-by": "publisher", "first-page": "1759", "DOI": "10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A", "volume": "92", "author": "J.L. Blum", "year": "2001", "unstructured": "Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759\u20131768", "journal-title": "Cancer"}, {"key": "19_CR11", "doi-asserted-by": "publisher", "first-page": "5138", "DOI": "10.1200/JCO.2005.04.120", "volume": "23", "author": "F. Boccardo", "year": "2005", "unstructured": "Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23:5138\u20135147", "journal-title": "J Clin Oncol"}, {"key": "19_CR12", "doi-asserted-by": "publisher", "first-page": "1399", "DOI": "10.1093/annonc/mdg367", "volume": "14", "author": "J.J. Body", "year": "2003", "unstructured": "Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405", "journal-title": "Ann Oncol"}, {"key": "19_CR13", "doi-asserted-by": "publisher", "first-page": "1133", "DOI": "10.1038/sj.bjc.6601663", "volume": "90", "author": "J.J. Body", "year": "2004", "unstructured": "Body JJ, Diel IJ, Lichinitser MR et al (2004a) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133\u20131137", "journal-title": "Br J Cancer"}, {"key": "19_CR14", "doi-asserted-by": "publisher", "first-page": "306", "DOI": "10.1016/j.pain.2004.07.011", "volume": "111", "author": "J.J. Body", "year": "2004", "unstructured": "Body JJ, Diel IJ, Bell R et al (2004b) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306\u2013312", "journal-title": "Pain"}, {"key": "19_CR15", "doi-asserted-by": "publisher", "first-page": "1539", "DOI": "10.1093/jnci/82.19.1539", "volume": "82", "author": "G. Bonadonna", "year": "1990", "unstructured": "Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539\u20131545", "journal-title": "J Natl Cancer Inst"}, {"key": "19_CR16", "doi-asserted-by": "publisher", "first-page": "2247", "DOI": "10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y", "volume": "92", "author": "J. Bonneterre", "year": "2001", "unstructured": "Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247\u20132258", "journal-title": "Cancer"}, {"key": "19_CR17", "doi-asserted-by": "crossref", "first-page": "1466", "DOI": "10.1038/sj.bjc.6602179", "volume": "91", "author": "J. Bonneterre", "year": "2004", "unstructured": "Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N, Bendahmane B (2004) Phase II multicentre randomized study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91:1466\u20131471", "journal-title": "Br J Cancer"}, {"key": "19_CR18", "doi-asserted-by": "publisher", "first-page": "7081", "DOI": "10.1200/JCO.2005.06.236", "volume": "23", "author": "M. Bontenbal", "year": "2005", "unstructured": "Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23:7081\u20137088", "journal-title": "J Clin Oncol"}, {"key": "19_CR19", "doi-asserted-by": "crossref", "first-page": "628", "DOI": "10.1200/JCO.2001.19.3.628", "volume": "19", "author": "R.A. Brito", "year": "2001", "unstructured": "Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN (2001) Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628\u2013633", "journal-title": "J Clin Oncol"}, {"key": "19_CR20", "first-page": "1142", "volume": "83", "author": "A.U. Buzdar", "year": "1998", "unstructured": "Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 83:1142\u20131152", "journal-title": "Arimidex Study Group Cancer"}, {"key": "19_CR21", "doi-asserted-by": "crossref", "first-page": "3357", "DOI": "10.1200/JCO.2001.19.14.3357", "volume": "19", "author": "A. Buzdar", "year": "2001", "unstructured": "Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357\u20133366", "journal-title": "J Clin Oncol"}, {"key": "19_CR22", "first-page": "1073", "volume": "8", "author": "A.U. Buzdar", "year": "2002", "unstructured": "Buzdar AU, Singletary SE, Valero V et al (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073\u20131079", "journal-title": "Clin Cancer Res"}, {"key": "19_CR23", "doi-asserted-by": "publisher", "first-page": "3676", "DOI": "10.1200/JCO.2005.07.032", "volume": "23", "author": "A.U. Buzdar", "year": "2005", "unstructured": "Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676\u20133685", "journal-title": "J Clin Oncol"}, {"key": "19_CR24", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1200/jco.2005.23.16_suppl.581", "volume": "23", "author": "S. Chan", "year": "2005", "unstructured": "Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch M, Schneeweiss A, Llombart A, Carrasco E, Fumoleau P (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. Proc Am Soc Clin Oncol 23:581", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "19_CR25", "unstructured": "Chia SKL, Speers C, Kang A, D\u2019Yachkova Y, Malfair Taylor S, Barnett J, Coldman A, Gelmon K, Olivotto I (2003) The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc Am Soc Clin Oncol 22 (abstract 22)"}, {"key": "19_CR26", "doi-asserted-by": "publisher", "first-page": "6622", "DOI": "10.1158/1078-0432.CCR-04-0380", "volume": "10", "author": "M. Colleoni", "year": "2004", "unstructured": "Colleoni M, Viale G, Zahrieh D et al (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622\u20136628", "journal-title": "Clin Cancer Res"}, {"key": "19_CR27", "doi-asserted-by": "crossref", "first-page": "2552", "DOI": "10.1200/JCO.1996.14.9.2552", "volume": "14", "author": "P.F. Conte", "year": "1996", "unstructured": "Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 14:2552\u20132559", "journal-title": "J Clin Oncol"}, {"key": "19_CR28", "doi-asserted-by": "publisher", "first-page": "1081", "DOI": "10.1056/NEJMoa040331", "volume": "350", "author": "R.C. Coombes", "year": "2004", "unstructured": "Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092", "journal-title": "N Engl J Med"}, {"key": "19_CR29", "unstructured": "Coombes RC, Paridaens R, Jassem J et al (2006) First mature analysis of the Intergroup Exemestane Study. Proc Am Soc Clin Oncol, Part I. Vol 24, No. 18S (abstract LBA527)"}, {"key": "19_CR30", "unstructured": "Cristofanilli M, Boussen H, Baselga J et al (2006) A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 100 (abstract 1)"}, {"key": "19_CR31", "doi-asserted-by": "publisher", "first-page": "975", "DOI": "10.1016/S0360-3016(99)00103-0", "volume": "44", "author": "B. Naeyer De", "year": "1999", "unstructured": "De Naeyer B, De Meerleer G, Braems S, Vakaet L, Huys J (1999) Collagen vascular diseases and radiation therapy: A critical review. Int J Radiat Oncol Biol Phys 44:975\u2013980", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "19_CR32", "doi-asserted-by": "publisher", "first-page": "1681", "DOI": "10.1056/NEJM198812293192601", "volume": "319", "author": "Early Breast Cancer Trialists Collaborative Group", "year": "1988", "unstructured": "Early Breast Cancer Trialists Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 319:1681\u20131692", "journal-title": "N Engl J Med"}, {"key": "19_CR33", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1016/0140-6736(92)90997-H", "volume": "339", "author": "Early Breast Cancer Trialists Collaborative Group", "year": "1988", "unstructured": "Early Breast Cancer Trialists Collaborative Group (1988) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71\u201385", "journal-title": "Lancet"}, {"key": "19_CR34", "doi-asserted-by": "publisher", "first-page": "1189", "DOI": "10.1016/S0140-6736(05)66228-9", "volume": "348", "author": "Early Breast Cancer Trialists Collaborative Group", "year": "1996", "unstructured": "Early Breast Cancer Trialists Collaborative Group (1996)Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348:1189\u20131196", "journal-title": "Lancet"}, {"key": "19_CR35", "doi-asserted-by": "publisher", "first-page": "930", "DOI": "10.1016/S0140-6736(05)61359-1", "volume": "352", "author": "Early Breast Cancer Trialists Group", "year": "1998", "unstructured": "Early Breast Cancer Trialists Group (1998a) Polychemotherapy for early breast cancer; an overview of the randomised trials. Lancet 352:930\u2013942", "journal-title": "Lancet"}, {"key": "19_CR36", "doi-asserted-by": "publisher", "first-page": "1451", "DOI": "10.1016/S0140-6736(97)11423-4", "volume": "351", "author": "Early Breast Cancer Trialists Group", "year": "1998", "unstructured": "Early Breast Cancer Trialists Group (1998b) Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 351:1451\u20131467", "journal-title": "Lancet"}, {"key": "19_CR37", "doi-asserted-by": "publisher", "first-page": "1687", "DOI": "10.1016/S0140-6736(05)66544-0", "volume": "365", "author": "Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)", "year": "2005", "unstructured": "Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717", "journal-title": "Lancet"}, {"key": "19_CR38", "doi-asserted-by": "publisher", "first-page": "1527", "DOI": "10.1023/A:1013128213451", "volume": "12", "author": "W. Eiermann", "year": "2001", "unstructured": "Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527\u20131532", "journal-title": "Ann Oncol"}, {"key": "19_CR39", "doi-asserted-by": "publisher", "first-page": "4956", "DOI": "10.1200/JCO.2005.05.1235", "volume": "24", "author": "B. Ejlertsen", "year": "2006", "unstructured": "Ejlertsen B, Mouridsen HT, Jensen M et al (2006) Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive breast cancer. J Clin Oncol 24:4956\u20134962", "journal-title": "J Clin Oncol"}, {"key": "19_CR40", "first-page": "CD003139", "volume": "3", "author": "C. Farquhar", "year": "2005", "unstructured": "Farquhar C, Marjoribanks J, Basser R, Lethaby A (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer (Review). Cochrane Database Syst Rev (3): CD003139", "journal-title": "Cochrane Database Syst Rev"}, {"key": "19_CR41", "author": "J. Ferlay", "year": "1999", "unstructured": "Ferlay J, Bray F, Sankila R, Parkin DM (1999) EUCAN: Cancer incidence, mortality and prevalence in the European Union 1998, version 5.0. IARC Cancer Base No. 4, IARC-Press, Lyon", "volume-title": "IARC Cancer Base"}, {"key": "19_CR42", "author": "J. Ferlay", "year": "2004", "unstructured": "Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. version 2.0, IARC-Press, Lyon", "volume-title": "IARC Cancer Base"}, {"key": "19_CR43", "doi-asserted-by": "publisher", "first-page": "1456", "DOI": "10.1056/NEJM199511303332203", "volume": "333", "author": "B. Fisher", "year": "1995", "unstructured": "Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456\u20131461", "journal-title": "N Engl J Med"}, {"key": "19_CR44", "doi-asserted-by": "crossref", "first-page": "2483", "DOI": "10.1200/JCO.1997.15.7.2483", "volume": "15", "author": "B. Fisher", "year": "1997", "unstructured": "Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483\u20132493", "journal-title": "J Clin Oncol"}, {"key": "19_CR45", "doi-asserted-by": "crossref", "first-page": "2672", "DOI": "10.1200/JCO.1998.16.8.2672", "volume": "16", "author": "B. Fisher", "year": "1998", "unstructured": "Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672\u20132685", "journal-title": "J Clin Oncol"}, {"key": "19_CR46", "doi-asserted-by": "publisher", "first-page": "681", "DOI": "10.1002/cncr.10741", "volume": "95", "author": "E.R. Fisher", "year": "2002", "unstructured": "Fisher ER, Wang J, Bryant J et al (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681\u2013695", "journal-title": "Cancer"}, {"key": "19_CR47", "doi-asserted-by": "crossref", "first-page": "3439", "DOI": "10.1200/JCO.1998.16.10.3439", "volume": "16", "author": "R. Fossati", "year": "1998", "unstructured": "Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439\u20133460", "journal-title": "J Clin Oncol"}, {"key": "19_CR48", "doi-asserted-by": "crossref", "first-page": "3596", "DOI": "10.1200/JCO.1999.17.11.3596", "volume": "17", "author": "A. Gennari", "year": "1999", "unstructured": "Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17:3596\u20133602", "journal-title": "J Clin Oncol"}, {"key": "19_CR49", "doi-asserted-by": "publisher", "first-page": "962", "DOI": "10.1038/sj.bjc.6601634", "volume": "90", "author": "A. Gennari", "year": "2004", "unstructured": "Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, Guarneri V, Rondini M, Ricci S, Conte P (2004) Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 90:962\u2013967", "journal-title": "Br J Cancer"}, {"key": "19_CR50", "doi-asserted-by": "publisher", "first-page": "1742", "DOI": "10.1002/cncr.21359", "volume": "104", "author": "A. Gennari", "year": "2005", "unstructured": "Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742\u20131750", "journal-title": "Cancer"}, {"key": "19_CR51", "doi-asserted-by": "publisher", "first-page": "2733", "DOI": "10.1056/NEJMoa064320", "volume": "355", "author": "C.E. Geyer", "year": "2006", "unstructured": "Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743", "journal-title": "N Engl J Med"}, {"key": "19_CR52", "unstructured": "Ghersi D, Wilcken N, Simes J, Donoghue E (2006) Taxane containing regimens for metastatic breast cancer. The Cochrane Library 2006: issue 3", "DOI": "10.1002/14651858.CD003366.pub2", "doi-asserted-by": "crossref"}, {"key": "19_CR53", "doi-asserted-by": "publisher", "first-page": "8715", "DOI": "10.1158/1078-0432.CCR-05-0539", "volume": "11", "author": "L. Gianni", "year": "2005", "unstructured": "Gianni L, Baselga J, Eiermann W et al (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and Its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715\u20138721", "journal-title": "Clin Cancer Res"}, {"key": "19_CR54", "doi-asserted-by": "crossref", "first-page": "2345", "DOI": "10.1200/JCO.1997.15.6.2345", "volume": "15", "author": "A.E. Giuliano", "year": "1997", "unstructured": "Giuliano AE, Jones RC, Brennan M, Statman R (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345\u20132350", "journal-title": "J Clin Oncol"}, {"key": "19_CR55", "doi-asserted-by": "publisher", "first-page": "1569", "DOI": "10.1093/annonc/mdi326", "volume": "16", "author": "A. Goldhirsch", "year": "2005", "unstructured": "Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569\u20131583", "journal-title": "Ann Oncol"}, {"key": "19_CR56", "unstructured": "Goldstein LJ, O\u2019Neill A, Sparano JA et al (2005) E2197: a phase III of AT vs AC in the adjuvant treatment of nodepositive and high-risk node-negative breast cancer. Proc Am Soc Clin Oncol 23 (abstract 512)", "DOI": "10.1200/jco.2005.23.16_suppl.512", "doi-asserted-by": "crossref"}, {"key": "19_CR57", "doi-asserted-by": "publisher", "first-page": "1793", "DOI": "10.1056/NEJMoa032312", "volume": "349", "author": "P.E. Goss", "year": "2003", "unstructured": "Goss PE, Ingle JN, Martino S et al (2003). A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802", "journal-title": "N Engl J Med"}, {"key": "19_CR58", "unstructured": "Gradishar W, Chia S, Piccart M, on behalf of the EFECT writing committee (2006) Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res and Treat 100 (abstract 12)"}, {"key": "19_CR59", "doi-asserted-by": "publisher", "first-page": "1037", "DOI": "10.1200/JCO.2005.02.6914", "volume": "24", "author": "V. Guarneri", "year": "2006", "unstructured": "Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037\u20131044", "journal-title": "J Clin Oncol"}, {"key": "19_CR60", "unstructured": "Haskell CM, Green SJ, Sledge GW, Shapiro CL, Ingle JN, Lew D, Martino S, Livingston RB, Osborne C (2002) Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0\u20133 positive nodes (intergroup 0137). Proc Am Soc Clin Oncol 21 (abstr 142)"}, {"key": "19_CR61", "doi-asserted-by": "publisher", "first-page": "976", "DOI": "10.1200/JCO.2003.02.063", "volume": "21", "author": "I.C. Henderson", "year": "2003", "unstructured": "Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976\u2013983", "journal-title": "J Clin Oncol"}, {"key": "19_CR62", "doi-asserted-by": "publisher", "first-page": "9304", "DOI": "10.1200/JCO.2005.02.5023", "volume": "23", "author": "B.T. Hennessy", "year": "2005", "unstructured": "Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304\u20139311", "journal-title": "J Clin Oncol"}, {"key": "19_CR63", "doi-asserted-by": "publisher", "first-page": "4042", "DOI": "10.1200/JCO.2003.08.017", "volume": "21", "author": "B.E. Hilner", "year": "2003", "unstructured": "Hilner BE, Ingle JN, Chelbowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057", "journal-title": "J Clin Oncol"}, {"key": "19_CR64", "doi-asserted-by": "publisher", "first-page": "2507", "DOI": "10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D", "volume": "62", "author": "G.N. Hortobagyi", "year": "1988", "unstructured": "Hortobagyi GN, Ames FC, Budzar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62:2507\u20132516", "journal-title": "Cancer"}, {"key": "19_CR65", "doi-asserted-by": "crossref", "first-page": "2038", "DOI": "10.1200/JCO.1998.16.6.2038", "volume": "16", "author": "G.N. Hortobagyi", "year": "1998", "unstructured": "Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038\u20132044", "journal-title": "J Clin Oncol"}, {"key": "19_CR66", "doi-asserted-by": "publisher", "first-page": "3396", "DOI": "10.1200/JCO.2002.10.057", "volume": "20", "author": "A. Howell", "year": "2002", "unstructured": "Howell A, Robertson JF, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396\u20133403", "journal-title": "J Clin Oncol"}, {"key": "19_CR67", "doi-asserted-by": "publisher", "first-page": "1605", "DOI": "10.1200/JCO.2004.02.112", "volume": "22", "author": "A. Howell", "year": "2004", "unstructured": "Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605\u20131613", "journal-title": "J Clin Oncol"}, {"key": "19_CR68", "doi-asserted-by": "publisher", "first-page": "60", "DOI": "10.1016/S0140-6736(05)74803-0", "volume": "365", "author": "A. Howell", "year": "2005", "unstructured": "Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362", "journal-title": "Lancet"}, {"key": "19_CR69", "unstructured": "Hudis C, Citron ML, Berry DA et al (2005) Five-year followup of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 94 (abstract 41)"}, {"key": "19_CR70", "unstructured": "Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P (2006) NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Proc Am Soc Clin Oncol. Part I. Vol 24, No. 18S (abstract 549)"}, {"key": "19_CR71", "doi-asserted-by": "publisher", "first-page": "907", "DOI": "10.1056/NEJM199504063321402", "volume": "332", "author": "J.A. Jacobson", "year": "1995", "unstructured": "Jacobson JA, Danforth DN, Cowan KH et al (1995) Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332:907\u2013911", "journal-title": "N Engl J Med"}, {"key": "19_CR72", "doi-asserted-by": "crossref", "first-page": "1707", "DOI": "10.1200/JCO.2001.19.6.1707", "volume": "19", "author": "J. Jassem", "year": "2001", "unstructured": "Jassem J, Pienkowski T, Pluzanska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707\u20131715", "journal-title": "J Clin Oncol"}, {"key": "19_CR73", "doi-asserted-by": "publisher", "first-page": "809", "DOI": "10.1056/NEJMoa053028", "volume": "354", "author": "H. Joensuu", "year": "2006", "unstructured": "Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809\u2013820", "journal-title": "N Engl J Med"}, {"key": "19_CR74", "doi-asserted-by": "publisher", "first-page": "991", "DOI": "10.1016/S1470-2045(06)70948-2", "volume": "7", "author": "W. Jonat", "year": "2006", "unstructured": "Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7:991\u2013996", "journal-title": "Lancet Oncol"}, {"key": "19_CR75", "unstructured": "Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja SJ, George TK, McIntyre KJ, Pippen JE, Sandbach J, Kirby RL, Bordelon JH, Hyman WJ, Negron AG, Khandelwal P, Richards DA, Anthony S, Nugent JE, Mennel RG, Banerji M, Edelman G, Ruxer RL, Amare M, Kampe CE, Koutrelakos N, Meyer WG, Asmar L (2005) Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1,016 women with early stage breast cancer. Breast Cancer Res Treat 94 (abstract 40)"}, {"key": "19_CR76", "doi-asserted-by": "publisher", "first-page": "1711", "DOI": "10.1016/S0959-8049(03)00392-7", "volume": "39", "author": "M. Kaufmann", "year": "2003", "unstructured": "Kaufmann M, Jonat W, Blamey R et al (2003) Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711\u20131717", "journal-title": "Eur J Cancer"}, {"key": "19_CR77", "doi-asserted-by": "crossref", "first-page": "343", "DOI": "10.1200/JCO.2001.19.2.343", "volume": "19", "author": "J.G. Klijn", "year": "2001", "unstructured": "Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Hormone Agents Trialists\u2019 Group and the European Organization for Research and Treatment of Cancer (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Clin Oncol 19:343\u2013353", "journal-title": "Clin Oncol"}, {"key": "19_CR78", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1056/NEJM199810013391401", "volume": "339", "author": "D. Krag", "year": "1998", "unstructured": "Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer: A multicenter validation study. N Engl J Med 339:941\u2013946", "journal-title": "N Engl J Med"}, {"key": "19_CR79", "doi-asserted-by": "crossref", "first-page": "1399", "DOI": "10.1200/JCO.2000.18.7.1399", "volume": "18", "author": "M. Kufmann", "year": "2000", "unstructured": "Kufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399\u20131411", "journal-title": "J Clin Oncol"}, {"key": "19_CR80", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1097/00000658-199007000-00006", "volume": "212", "author": "J.M. Kurtz", "year": "1990", "unstructured": "Kurtz JM, Jacquemier J, Amalric R et al (1990) Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 212:38\u201344", "journal-title": "Ann Surg"}, {"key": "19_CR81", "doi-asserted-by": "publisher", "first-page": "8322", "DOI": "10.1200/JCO.2005.01.1817", "volume": "23", "author": "R.E. Langley", "year": "2005", "unstructured": "Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M (2005) Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23:8322\u20138330", "journal-title": "J Clin Oncol"}, {"key": "19_CR82", "first-page": "1429", "volume": "7", "author": "F.Y. Lee", "year": "2001", "unstructured": "Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429\u20131437", "journal-title": "Clin Cancer Res"}, {"key": "19_CR83", "doi-asserted-by": "publisher", "first-page": "5166", "DOI": "10.1200/JCO.2005.09.423", "volume": "23", "author": "M.N. Levine", "year": "2005", "unstructured": "Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N (2005) National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166\u20135170", "journal-title": "J Clin Oncol"}, {"key": "19_CR84", "doi-asserted-by": "publisher", "first-page": "375", "DOI": "10.1093/carcin/bgh019", "volume": "25", "author": "T. Lindahl", "year": "2004", "unstructured": "Lindahl T, Landberg G, Ahlgren J et al (2004) Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 25:375\u2013380", "journal-title": "Carcinogenesis"}, {"key": "19_CR85", "doi-asserted-by": "crossref", "first-page": "2234", "DOI": "10.1200/JCO.2000.18.11.2234", "volume": "18", "author": "P.E. Lonning", "year": "2000", "unstructured": "Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234\u20132244", "journal-title": "J Clin Oncol"}, {"key": "19_CR86", "doi-asserted-by": "publisher", "first-page": "2726", "DOI": "10.1200/JCO.2005.10.024", "volume": "23", "author": "J.A. Low", "year": "2005", "unstructured": "Low JA, Wedam SB, Lee JJ et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726\u20132734", "journal-title": "J Clin Oncol"}, {"key": "19_CR87", "first-page": "73", "volume": "19", "author": "H.J. Luck", "year": "2000", "unstructured": "Luck HJ, Thomssen C, Untch M et al (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC): a study of the AGO Breast Cancer Group [abstract]. Proc Am Soc Clin Oncol 19:73", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "19_CR88", "doi-asserted-by": "publisher", "first-page": "7703", "DOI": "10.1200/JCO.2005.08.001", "volume": "23", "author": "G.H. Lyman", "year": "2005", "unstructured": "Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703\u20137720", "journal-title": "J Clin Oncol"}, {"key": "19_CR89", "unstructured": "Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz JM (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 35 (abstract 137)"}, {"key": "19_CR90", "doi-asserted-by": "publisher", "first-page": "3686", "DOI": "10.1200/JCO.2005.10.517", "volume": "23", "author": "E.P. Mamounas", "year": "2005", "unstructured": "Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686\u20133696", "journal-title": "J Clin Oncol"}, {"key": "19_CR91", "doi-asserted-by": "publisher", "first-page": "2302", "DOI": "10.1056/NEJMoa043681", "volume": "352", "author": "M. Martin", "year": "2005", "unstructured": "Martin M, Pienkowski T, Mackey J et al (2005a) Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313", "journal-title": "N Engl J Med"}, {"key": "19_CR92", "unstructured": "Martin M, Rodriguez-Lescure A, Ruiz A et al (2005b) Multicenter, randomized phase III study of adjuvant chemotherapy for node-positive breast cancer comparing 6 cycles of FEC versus 4 cycles of FEC followed by 8 weekly paclitaxel administrations: interim analysis of GEICAM 9906 trial. Breast Cancer Res Treat 94 (abstract 39)", "DOI": "10.1200/jco.2004.22.14_suppl.596", "doi-asserted-by": "crossref"}, {"key": "19_CR93", "doi-asserted-by": "publisher", "first-page": "4265", "DOI": "10.1200/JCO.2005.04.173", "volume": "23", "author": "M. Marty", "year": "2005", "unstructured": "Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O\u2019Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer given as first-line treatment: results of a randomized phase III trial by the M7701 study group. J Clin Oncol 23:4265\u20134274", "journal-title": "J Clin Oncol"}, {"key": "19_CR94", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1097/00001813-200303000-00007", "volume": "14", "author": "U. Mey", "year": "2003", "unstructured": "Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IG (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14:233\u2013238", "journal-title": "Anticancer Drugs"}, {"key": "19_CR95", "doi-asserted-by": "publisher", "first-page": "792", "DOI": "10.1200/JCO.2005.05.098", "volume": "23", "author": "K.D. Miller", "year": "2005", "unstructured": "Miller KD, Chap LI, Holmes FA et al (2005a) Randomized phase III trial of capecitabine compared with bevacizumab in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792\u2013799", "journal-title": "J Clin Oncol"}, {"key": "19_CR96", "unstructured": "Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE (2005b) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94 (abstract 3)"}, {"key": "19_CR97", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.3816/CBC.2005.n.011", "volume": "6", "author": "F. Montemurro", "year": "2005", "unstructured": "Montemurro F, Aglietta M (2005) Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 6:77\u201380", "journal-title": "Clin Breast Cancer"}, {"key": "19_CR98", "doi-asserted-by": "crossref", "first-page": "2596", "DOI": "10.1200/JCO.2001.19.10.2596", "volume": "19", "author": "H. Mouridsen", "year": "2001", "unstructured": "Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596\u20132606", "journal-title": "J Clin Oncol"}, {"key": "19_CR99", "doi-asserted-by": "crossref", "first-page": "1413", "DOI": "10.1200/JCO.1999.17.5.1413", "volume": "17", "author": "J.M. Nabholtz", "year": "1999", "unstructured": "Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413\u20131424", "journal-title": "J Clin Oncol"}, {"key": "19_CR100", "doi-asserted-by": "crossref", "first-page": "3758", "DOI": "10.1200/JCO.2000.18.22.3758", "volume": "18", "author": "J.M. Nabholtz", "year": "2000", "unstructured": "Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as firstline therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. Arimidex Study Group. J Clin Oncol 18:3758\u20133776", "journal-title": "J Clin Oncol"}, {"key": "19_CR101", "doi-asserted-by": "publisher", "first-page": "968", "DOI": "10.1200/JCO.2003.04.040", "volume": "21", "author": "J.M. Nabholtz", "year": "2003", "unstructured": "Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975", "journal-title": "J Clin Oncol"}, {"key": "19_CR102", "doi-asserted-by": "publisher", "first-page": "440", "DOI": "10.1093/annonc/mdh097", "volume": "15", "author": "M. O\u2019Brien", "year": "2004", "unstructured": "O\u2019Brien M, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440\u2013449", "journal-title": "Ann Oncol"}, {"key": "19_CR103", "doi-asserted-by": "publisher", "first-page": "3386", "DOI": "10.1200/JCO.2002.10.058", "volume": "20", "author": "C.K. Osborne", "year": "2002", "unstructured": "Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386\u20133395", "journal-title": "J Clin Oncol"}, {"key": "19_CR104", "doi-asserted-by": "publisher", "first-page": "2812", "DOI": "10.1200/JCO.2002.09.002", "volume": "20", "author": "J. O\u2019Shaughnessy", "year": "2002", "unstructured": "O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812\u20132823", "journal-title": "J Clin Oncol"}, {"key": "19_CR105", "doi-asserted-by": "crossref", "first-page": "1668", "DOI": "10.1200/JCO.2000.18.8.1668", "volume": "18", "author": "C.C. Park", "year": "2000", "unstructured": "Park CC, Mitsumori M, Nixon A et al (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18:1668\u20131675", "journal-title": "J Clin Oncol"}, {"key": "19_CR106", "unstructured": "Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer (review). The Cochrane Library 2005, Issue 3", "DOI": "10.1002/14651858.CD003474.pub2", "doi-asserted-by": "crossref"}, {"key": "19_CR107", "doi-asserted-by": "publisher", "first-page": "900", "DOI": "10.1056/NEJM199809243391307", "volume": "339", "author": "K.S. Pawan", "year": "1998", "unstructured": "Pawan KS, Iliskovic N (1998) Doxorubicin-induced cardiomiopathy. N Engl J Med 339:900\u2013905", "journal-title": "N Engl J Med"}, {"key": "19_CR108", "doi-asserted-by": "publisher", "first-page": "64", "DOI": "10.1093/annonc/mdl341", "volume": "18", "author": "L. Perey", "year": "2007", "unstructured": "Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, Fiche M, Dietrich D, Clement P, Koberle D, Goldhirsch A, Thurlimann B (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18:64\u201369", "journal-title": "Ann Oncol"}, {"key": "19_CR109", "doi-asserted-by": "crossref", "first-page": "4216", "DOI": "10.1200/JCO.2001.19.22.4216", "volume": "19", "author": "E.A. Perez", "year": "2001", "unstructured": "Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216\u20134223", "journal-title": "J Clin Oncol"}, {"key": "19_CR110", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1200/JCO.1988.6.2.261", "volume": "6", "author": "M. Perloff", "year": "1988", "unstructured": "Perloff M, Lesnick GJ, Korzun A et al (1988) Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 6:261\u2013269", "journal-title": "J Clin Oncol"}, {"key": "19_CR111", "doi-asserted-by": "publisher", "first-page": "1659", "DOI": "10.1056/NEJMoa052306", "volume": "353", "author": "M.J. Piccart-Gebhart", "year": "2005", "unstructured": "Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672", "journal-title": "N Engl J Med"}, {"key": "19_CR112", "doi-asserted-by": "crossref", "first-page": "3360", "DOI": "10.1200/JCO.2000.18.19.3360", "volume": "18", "author": "L.J. Pierce", "year": "2000", "unstructured": "Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360\u20133369", "journal-title": "J Clin Oncol"}, {"key": "19_CR113", "doi-asserted-by": "publisher", "first-page": "1480", "DOI": "10.1054/bjoc.2000.1461", "volume": "83", "author": "J.Y. Pierga", "year": "2000", "unstructured": "Pierga JY, Mouret E, Dieras V et al (2000) Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480\u20131487", "journal-title": "Br J Cancer"}, {"key": "19_CR114", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1016/S1470-2045(05)70176-5", "volume": "6", "author": "A. Polychronis", "year": "2005", "unstructured": "Polychronis A, Sinnett HD, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383\u2013391", "journal-title": "Lancet Oncol"}, {"key": "19_CR115", "unstructured": "Poole CJ, Earl M, Dunn JA et al (2003) NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 22 (abstr 13)"}, {"key": "19_CR116", "doi-asserted-by": "publisher", "first-page": "869", "DOI": "10.1136/bmj.284.6319.869-a", "volume": "284", "author": "P.E. Preece", "year": "1982", "unstructured": "Preece PE, Wood RAB, Mackie CR, Cuschieri A (1982) Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study. Br Med J 284:869\u2013870", "journal-title": "Br Med J"}, {"key": "19_CR117", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1200/JCO.1996.14.1.46", "volume": "14", "author": "S. Rivkin", "year": "1996", "unstructured": "Rivkin S, Green S, O.Sullivan J, Cruz A, Abeloff M, Jewell W, Costanzi J, Farrar W, Osborne C (1996) Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 14:46\u201351", "journal-title": "J Clin Oncol"}, {"key": "19_CR118", "unstructured": "Roche H, Fumoleau P, Spielman M et al (2004) Five years analysis of the PAC01 trial: 6 cycles of FEC 100 versus 3 cycles of FEC 100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 88 (abstract 27)"}, {"key": "19_CR119", "doi-asserted-by": "publisher", "first-page": "1673", "DOI": "10.1056/NEJMoa052122", "volume": "353", "author": "E.H. Romond", "year": "2005", "unstructured": "Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684", "journal-title": "N Engl J Med"}, {"key": "19_CR120", "doi-asserted-by": "publisher", "first-page": "1735", "DOI": "10.1002/cncr.11701", "volume": "98", "author": "L.S. Rosen", "year": "2003", "unstructured": "Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744", "journal-title": "Cancer"}, {"key": "19_CR121", "first-page": "1293", "volume": "341", "author": "Scottish Cancer Trials Breast Group", "year": "1993", "unstructured": "Scottish Cancer Trials Breast Group (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet 341:1293\u20131298", "journal-title": "Lancet"}, {"key": "19_CR122", "doi-asserted-by": "publisher", "first-page": "1194", "DOI": "10.1016/S0959-8049(99)00122-7", "volume": "35", "author": "J. Sjostrom", "year": "1999", "unstructured": "Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194\u20131201", "journal-title": "Eur J Cancer"}, {"key": "19_CR123", "doi-asserted-by": "publisher", "first-page": "783", "DOI": "10.1056/NEJM200103153441101", "volume": "344", "author": "D.J. Slamon", "year": "2001", "unstructured": "Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792", "journal-title": "N Engl J Med"}, {"key": "19_CR124", "unstructured": "Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan M, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 (abstract 1)"}, {"key": "19_CR125", "doi-asserted-by": "publisher", "first-page": "588", "DOI": "10.1200/JCO.2003.08.013", "volume": "21", "author": "G.W. Sledge", "year": "2003", "unstructured": "Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel, as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588\u2013592", "journal-title": "J Clin Oncol"}, {"key": "19_CR126", "doi-asserted-by": "publisher", "first-page": "1456", "DOI": "10.1200/JCO.20.6.1456", "volume": "20", "author": "I.C. Smith", "year": "2002", "unstructured": "Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456\u20131466", "journal-title": "J Clin Oncol"}, {"key": "19_CR127", "doi-asserted-by": "publisher", "first-page": "5108", "DOI": "10.1200/JCO.2005.04.005", "volume": "23", "author": "I.E. Smith", "year": "2005", "unstructured": "Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108\u20135116", "journal-title": "J Clin Oncol"}, {"key": "19_CR128", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/S0140-6736(07)60028-2", "volume": "369", "author": "I. Smith", "year": "2007", "unstructured": "Smith I, Procter M, Gelber RD et al (2007) Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29\u201336", "journal-title": "Lancet"}, {"key": "19_CR129", "doi-asserted-by": "publisher", "first-page": "10869", "DOI": "10.1073/pnas.191367098", "volume": "98", "author": "T. Sorlie", "year": "2001", "unstructured": "Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98:10869\u201310874", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "19_CR130", "unstructured": "Sparano JA, Wang M, Martino S et al (2005) From the Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Acute Leukemia Group B (CALBG), and the North Central Cancer Treatment Group (NCCTG). Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary nodepositive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat 94 (abstract 48)"}, {"key": "19_CR131", "first-page": "2997", "volume": "22", "author": "F. Spyratos", "year": "2002", "unstructured": "Spyratos F, Bouchet C, Tozlu S et al (2002) Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 22:2997\u20133003", "journal-title": "Anticancer Res"}, {"key": "19_CR132", "doi-asserted-by": "publisher", "first-page": "2747", "DOI": "10.1056/NEJMoa052258", "volume": "353", "author": "B. Thurlimann", "year": "2005", "unstructured": "Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757", "journal-title": "N Engl J Med"}, {"key": "19_CR133", "doi-asserted-by": "publisher", "first-page": "321", "DOI": "10.1007/s002800050664", "volume": "40", "author": "N.T. Ueno", "year": "1997", "unstructured": "Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321\u2013329", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "19_CR134", "doi-asserted-by": "publisher", "first-page": "1999", "DOI": "10.1056/NEJMoa021967", "volume": "347", "author": "M.J. Vijver Van de", "year": "2002", "unstructured": "Van de Vijver MJ, He YD, van\u2019t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999\u20132009", "journal-title": "N Engl J Med"}, {"key": "19_CR135", "doi-asserted-by": "publisher", "first-page": "1712", "DOI": "10.1093/jnci/dji438", "volume": "97", "author": "M. Venturini", "year": "2005", "unstructured": "Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97:1712\u20131714", "journal-title": "J Natl Cancer Inst"}, {"key": "19_CR136", "doi-asserted-by": "publisher", "first-page": "668", "DOI": "10.1016/0277-5379(90)90113-8", "volume": "26", "author": "U. Veronesi", "year": "1990", "unstructured": "Veronesi U, Banfi A, Salvadori B et al (1990) Breast conservation is the treatment of choice in small breast cancer: Long-term results of a randomized trial. Eur J Cancer 26:668\u2013670", "journal-title": "Eur J Cancer"}, {"key": "19_CR137", "doi-asserted-by": "publisher", "first-page": "56", "DOI": "10.1093/annonc/mdi001", "volume": "16", "author": "G. Minckwitz von", "year": "2005", "unstructured": "von Minckwitz G, Blohmer JU, Raab G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56\u201363", "journal-title": "Ann Oncol"}, {"key": "19_CR138", "doi-asserted-by": "publisher", "first-page": "1780", "DOI": "10.1016/j.ejca.2006.04.006", "volume": "42", "author": "G. Minckwitz von", "year": "2006", "unstructured": "von Minckwitz G, Graf E, Geberth M et al (2006) CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomized trial (GABG trial IV-A-93). Eur J Cancer 42:1780\u20131788", "journal-title": "Eur J Cancer"}, {"key": "19_CR139", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.1200/JCO.2005.03.4645", "volume": "24", "author": "S.B. Wedam", "year": "2006", "unstructured": "Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769\u2013777", "journal-title": "J Clin Oncol"}, {"key": "19_CR140", "doi-asserted-by": "publisher", "first-page": "2267", "DOI": "10.1002/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q", "volume": "92", "author": "L. Zelek", "year": "2001", "unstructured": "Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267\u20132272", "journal-title": "Cancer"}, {"key": "19_CR141", "doi-asserted-by": "publisher", "first-page": "1401", "DOI": "10.1200/JCO.2005.12.106", "volume": "23", "author": "C. Zielinski", "year": "2005", "unstructured": "Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 23:1401\u20131408", "journal-title": "J Clin Oncol"}, {"key": "19_CR142", "doi-asserted-by": "publisher", "first-page": "1422", "DOI": "10.1002/1097-0142(197603)37:3<1422::AID-CNCR2820370325>3.0.CO;2-Y", "volume": "37", "author": "R. Zucali", "year": "1976", "unstructured": "Zucali R, Uslenghi C, Kenda R, Bonadonna G (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed radical mastectomy. Cancer 37:1422\u20131431", "journal-title": "Cancer"}], "container-title": ["Breast Cancer"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-540-36781-9_19", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 6]], "date-time": "2019-05-06T05:38:20Z", "timestamp": 1557121100000}, "score": 22.976147, "issued": {"date-parts": [[null]]}, "ISBN": ["9783540367802", "9783540367819"], "references-count": 142, "URL": "http://dx.doi.org/10.1007/978-3-540-36781-9_19", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T19:15:46Z", "timestamp": 1574363746420}, "reference-count": 15, "publisher": "Elsevier BV", "issue": "8", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 4, 1]], "date-time": "2008-04-01T00:00:00Z", "timestamp": 1207008000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2008, 4]]}, "DOI": "10.1016/s1359-6349(08)70282-9", "type": "journal-article", "created": {"date-parts": [[2008, 4, 12]], "date-time": "2008-04-12T17:25:26Z", "timestamp": 1208021126000}, "page": "1-4", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The 2007 Rome Forum on the Treatment of Breast Cancer: first-line treatment choices for metastatic breast cancer in Europe"], "prefix": "10.1016", "volume": "6", "author": [{"given": "Pier Franco", "family": "Conte", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634908702829?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634908702829?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 30]], "date-time": "2018-12-30T05:24:04Z", "timestamp": 1546147444000}, "score": 22.944893, "issued": {"date-parts": [[2008, 4]]}, "references-count": 15, "journal-issue": {"published-print": {"date-parts": [[2008, 4]]}, "issue": "8"}, "alternative-id": ["S1359634908702829"], "URL": "http://dx.doi.org/10.1016/s1359-6349(08)70282-9", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T16:05:43Z", "timestamp": 1575216343574}, "reference-count": 0, "publisher": "Alphamed Press", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Oncologist"], "published-print": {"date-parts": [[2013, 4, 1]]}, "DOI": "10.1634/theoncologist.2013-0117", "type": "journal-article", "created": {"date-parts": [[2013, 4, 30]], "date-time": "2013-04-30T13:38:32Z", "timestamp": 1367329112000}, "page": "e8-e10", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Interpreting Cancer Biology: Refining Our Therapeutic Algorithm in Breast Cancer"], "prefix": "10.1634", "volume": "18", "author": [{"given": "G.", "family": "Hortobagyi", "sequence": "first", "affiliation": []}, {"given": "P.", "family": "Conte", "sequence": "additional", "affiliation": []}], "member": "638", "published-online": {"date-parts": [[2013, 4, 30]]}, "container-title": ["The Oncologist"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1634/theoncologist.2013-0117", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 22]], "date-time": "2016-12-22T23:59:01Z", "timestamp": 1482451141000}, "score": 22.703545, "issued": {"date-parts": [[2013, 4, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 4, 30]]}, "published-print": {"date-parts": [[2013, 4, 1]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1634/theoncologist.2013-0117", "ISSN": ["1083-7159", "1549-490X"], "issn-type": [{"value": "1083-7159", "type": "print"}, {"value": "1549-490X", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T17:03:43Z", "timestamp": 1575306223582}, "reference-count": 47, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2000, 9, 1]], "date-time": "2000-09-01T00:00:00Z", "timestamp": 967766400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2000, 9]]}, "DOI": "10.3816/cbc.2000.s.009", "type": "journal-article", "created": {"date-parts": [[2008, 9, 12]], "date-time": "2008-09-12T01:03:48Z", "timestamp": 1221181428000}, "page": "S46-S51", "source": "Crossref", "is-referenced-by-count": 16, "title": ["Role of Epirubicin in Advanced Breast Cancer"], "prefix": "10.3816", "volume": "1", "author": [{"given": "Pier Franco", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "Alessandra", "family": "Gennari", "sequence": "additional", "affiliation": []}, {"given": "Elisabetta", "family": "Landucci", "sequence": "additional", "affiliation": []}, {"given": "Cinzia", "family": "Orlandini", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S152682091170163X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S152682091170163X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 25]], "date-time": "2018-12-25T21:57:09Z", "timestamp": 1545775029000}, "score": 22.285934, "issued": {"date-parts": [[2000, 9]]}, "references-count": 47, "alternative-id": ["S152682091170163X"], "URL": "http://dx.doi.org/10.3816/cbc.2000.s.009", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:24:15Z", "timestamp": 1575185055850}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 4, 1]], "date-time": "2001-04-01T00:00:00Z", "timestamp": 986083200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Seminars in Oncology"], "published-print": {"date-parts": [[2001, 4]]}, "DOI": "10.1016/s0093-7754(01)90273-8", "type": "journal-article", "created": {"date-parts": [[2005, 11, 3]], "date-time": "2005-11-03T12:48:34Z", "timestamp": 1131022114000}, "page": "15-17", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer"], "prefix": "10.1016", "volume": "28", "author": [{"given": "P", "family": "CONTE", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0093775401902738?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0093775401902738?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 21]], "date-time": "2019-01-21T11:20:56Z", "timestamp": 1548069656000}, "score": 22.283003, "issued": {"date-parts": [[2001, 4]]}, "references-count": 0, "alternative-id": ["S0093775401902738"], "URL": "http://dx.doi.org/10.1016/s0093-7754(01)90273-8", "ISSN": ["0093-7754"], "issn-type": [{"value": "0093-7754", "type": "print"}], "subject": ["Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:54:09Z", "timestamp": 1574283249843}, "reference-count": 31, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 3, 1]], "date-time": "2009-03-01T00:00:00Z", "timestamp": 1235865600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2009, 3]]}, "DOI": "10.1016/s1359-6349(09)70005-9", "type": "journal-article", "created": {"date-parts": [[2009, 3, 3]], "date-time": "2009-03-03T09:19:18Z", "timestamp": 1236071958000}, "page": "14-18", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Triple-negative breast cancer: current management and future options"], "prefix": "10.1016", "volume": "7", "author": [{"given": "PierFranco", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "Valentina", "family": "Guarneri", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634909700059?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634909700059?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T10:59:15Z", "timestamp": 1558177155000}, "score": 22.11523, "issued": {"date-parts": [[2009, 3]]}, "references-count": 31, "journal-issue": {"published-print": {"date-parts": [[2009, 3]]}, "issue": "1"}, "alternative-id": ["S1359634909700059"], "URL": "http://dx.doi.org/10.1016/s1359-6349(09)70005-9", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"institution": {"name": "US Dept of the Army", "place": ["-", "-"], "department": ["Funding", "Performing"], "acronym": ["USAMRMC", "-"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T02:32:14Z", "timestamp": 1574821934117}, "publisher-location": "Fort Belvoir, VA", "reference-count": 0, "publisher": "Defense Technical Information Center", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2006, 5, 1]]}, "DOI": "10.21236/ada456044", "type": "report", "created": {"date-parts": [[2017, 8, 11]], "date-time": "2017-08-11T17:33:37Z", "timestamp": 1502472817000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Role of Conserved Oligomeric Golgi Complex in the Abnormalities of Glycoprotein Processing in Breast Cancer Cells"], "prefix": "10.21236", "author": [{"given": "Sergey N.", "family": "Zolov", "sequence": "first", "affiliation": []}], "member": "9879", "original-title": [""], "deposited": {"date-parts": [[2017, 8, 11]], "date-time": "2017-08-11T17:33:38Z", "timestamp": 1502472818000}, "score": 21.773651, "subtitle": [""], "issued": {"date-parts": [[2006, 5, 1]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21236/ada456044"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T02:54:46Z", "timestamp": 1574132086239}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "11", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2002, 3, 1]], "date-time": "2002-03-01T00:00:00Z", "timestamp": 1014940800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002, 3]]}, "DOI": "10.1016/s0959-8049(02)80141-1", "type": "journal-article", "created": {"date-parts": [[2002, 10, 11]], "date-time": "2002-10-11T16:45:26Z", "timestamp": 1034354726000}, "page": "S53", "source": "Crossref", "is-referenced-by-count": 0, "title": ["YB-1 expression (mRNA and protein) in sporadic breast cancer"], "prefix": "10.1016", "volume": "38", "author": [{"given": "N", "family": "Macpherson", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959-8049(02)80141-1?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959-8049(02)80141-1?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 11]], "date-time": "2019-04-11T10:57:19Z", "timestamp": 1554980239000}, "score": 21.584013, "issued": {"date-parts": [[2002, 3]]}, "references-count": 0, "journal-issue": {"issue": "11"}, "alternative-id": ["S0959-8049(02)80141-1"], "URL": "http://dx.doi.org/10.1016/s0959-8049(02)80141-1", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T01:31:16Z", "timestamp": 1574299876833}, "reference-count": 3, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2007, 2, 1]], "date-time": "2007-02-01T00:00:00Z", "timestamp": 1170288000000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2007, 2]]}, "DOI": "10.1186/bcr1697", "type": "journal-article", "created": {"date-parts": [[2007, 6, 19]], "date-time": "2007-06-19T18:13:52Z", "timestamp": 1182276832000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)"], "prefix": "10.1186", "volume": "9", "author": [{"given": "PF", "family": "Conte", "sequence": "first", "affiliation": []}, {"given": "V", "family": "Guarneri", "sequence": "additional", "affiliation": []}, {"given": "C", "family": "Bengala", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2007, 6, 19]]}, "reference": [{"key": "1662_CR1", "unstructured": "Conte PF, Bengala C, Guarneri V: Controversies of chemotherapy for the treatment of metastatic breast cancer. Eur J Cancer. 2007, 11-16. Suppl 5", "DOI": "10.1016/S1359-6349(07)70010-1", "doi-asserted-by": "crossref"}, {"issue": "Suppl 1", "key": "1662_CR2", "first-page": "S149", "volume": "31", "author": "PF Conte", "year": "2004", "unstructured": "Conte PF, Guarneri V: The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004, 31 (Suppl 1): S149-S161.", "journal-title": "Eur J Nucl Med Mol Imaging"}, {"key": "1662_CR3", "doi-asserted-by": "publisher", "first-page": "962", "DOI": "10.1038/sj.bjc.6601634", "volume": "90", "author": "A Gennari", "year": "2004", "unstructured": "Gennari A, Bruzzi P, Orlandini C, et al: Activity of first line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer. 2004, 90: 962-967. 10.1038/sj.bjc.6601634.", "journal-title": "Br J Cancer"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr1697.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr1697/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr1697.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 29]], "date-time": "2019-04-29T05:22:18Z", "timestamp": 1556515338000}, "score": 21.5569, "issued": {"date-parts": [[2007, 2]]}, "references-count": 3, "journal-issue": {"published-print": {"date-parts": [[2007, 2]]}, "issue": "S1"}, "alternative-id": ["1662"], "URL": "http://dx.doi.org/10.1186/bcr1697", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "article-number": "S14"}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}